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Abstract 
Objectives: To assess: i) utilization of generic anti-glaucoma drugs in Canada; ii) the 
impact of the 2010 Ontario Drug System Reform on generic anti-glaucoma drug usage in 
Ontario. 
Methods: Monthly drug insurance cost and claims from January 2001 to January 2013 
were used as proxies for drug utilization. Evaluation of the impact of the 2010 reform 
was conducted using interrupted time series analysis with ARIMA models. 
Results: Generic antiglaucoma medication utilization increased in Ontario during Quarter 
3, 2006. Increases in utilization across study provinces were observed in Quarter 4, 2011. 
The 2010 reform was not associated with changes in generic drug utilization. 
Conclusion: The results of the study demonstrated that introduction of new generic 
equivalents increases in the utilization of generics drugs. Lowering the price of generic 
medications did not lead to a change in the utilization. Alternative strategies should be 
implemented to increase generic drug use in glaucoma treatment.  
 
Keywords 
Ophthalmic medication, Glaucoma, Generic Drug, Drug utilization patterns, Time series, 
Interrupted time series analysis, Autoregressive Moving Average Model, Transparent 
Drug System for Patients Act, Bill 102, Ontario Drug System Reform. 
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Chapter 1  
1 Introduction 
Glaucoma is a chronic ocular disorder in which the optic nerve is systematically 
damaged, resulting in progressive vision loss. Treatments for glaucoma are focused 
towards the prevention of disease progression, and often begin with the use of topical 
ophthalmic medication. These medications aim to reduce intraocular pressure, and 
thereby reduce disease progression, through affecting aqueous humour dynamics. 
Currently, there are 5 major classes of antiglaucoma medication: cholinergic agonists, α-
adrenergic agonists, β-adrenergic receptor antagonists, carbonic anhydrase inhibitors, and 
prostaglandins. Generic equivalents for many of these medications are currently 
available.   
To address rising healthcare costs, various provincial government have enacted laws 
which limit the cost of generic medications. In Ontario, reforms to the provincial drug 
insurance program, Ontario Drug Benefit Program, were made in 2006 and 2010 with 
aims to cap the price of generic equivalents to 50% and 25% of the price of the reference 
product, respectively. Moreover, the 2010 reform enacted laws which extended price 
ceilings for the generic medication within the private market. While several studies have 
examined the impact of the reforms on overall drug expenditures within the public drug 
insurance program, none have looked at the impact specifically within the private and 
public antiglaucoma medication market. 
Hence, this study aimed to describe the utilization of generic antiglaucoma medication 
between January 2001 and January 2013 across several provinces in Canada. 
Furthermore, we made use of time series techniques to determine the impact of the 2010 
Ontario Drug System Reform on the dispensing of antiglaucoma medication across 
several Canadian provinces.  
The results of the study revealed that the utilization of antiglaucoma medication is 
heavily influenced by the introduction and availability of novel antiglaucoma medication, 
whether the drug is a generic or brand name compound. The impact of the drug plan 
2 
 
 
 
reforms remains relatively muted. Hence, in order to control rising healthcare costs, 
policy makers should consider alternative methods such as encouraging increases in 
utilization of generic medications for glaucoma treatment. 
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Chapter 2  
2 Literature Review 
2.1 Glaucoma: An Introduction 
Glaucoma is a group of ocular neuropathic disorders estimated to be the second leading 
cause of blindness worldwide.1,2 Commonly associated with increased intraocular 
pressure (IOP), vision loss due to glaucoma is caused by the gradual degeneration of 
retinal ganglion cells and their axons.3 As a result, the profile of the optic nerve head 
changes (“cupping”) and vision progressively deteriorates in a characteristic pattern, 
typically beginning with the peripheral vision. Glaucomatous vision loss is permanent as 
the disease damages the optic nerve, and is thus responsible as the leading cause of 
irreversible blindness worldwide. 
Fortunately, glaucoma progression can be controlled by efforts to reduce intraocular 
pressure, making this the leading cause of preventable blindness worldwide.4 Treatment 
often begins with the use of antiglaucoma medications aimed at the control or reduction 
of intraocular pressure. Once medication options have been exhausted, patients are 
referred for laser trabeculoplasty or more invasive intraocular surgeries in order to 
minimize progression of the disease.  
The prevalence of glaucoma increases significantly with age, and the problem of 
glaucoma will continue to increase as the world’s population ages.5–7 
2.2 Classification and Types of Glaucoma 
Glaucoma is classified based on 1) etiology or 2) mechanism. Etiology refers to 
classifying the type of glaucoma based on the underlying disease which leads to the 
modifications in aqueous humour dynamics or retinal ganglion cell loss.4 Etiological 
classification divides glaucoma into primary and secondary forms, where primary forms 
are thought to be a result of anterior chamber and conventional outflow pathway 
obstruction and is independent of other ocular or systemic disorders.4 On the other hand, 
classification of secondary glaucoma is dependent on a partial understanding of an 
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underlying, predisposing ocular or systemic event.4 While etiologic classifications are 
currently used extensively in clinical practice, its reliance on an incomplete 
understanding of the pathophysiology may limit its clinical relevance. Moreover, as the 
knowledge of the mechanisms behind the disease increases, mechanistic approaches to 
defining glaucoma offers an alternative classification system.4 
Mechanistic approaches to defining glaucoma aims to classify patients based on the 
mechanisms of aqueous outflow obstruction. These mechanisms are varied depending on 
the characteristics of the iridocorneal angle, the angle formed between the iris and cornea. 
This classification system separates glaucoma into three categories: a) open-angle 
glaucoma (OAG), b) angle-closure glaucoma (ACG) and c) developmental anomalies of 
the iridocorneal angle.4 
2.2.1 Open Angle Glaucoma 
In open-angle glaucoma, the iridocorneal angle remains unobstructed, but the outflow of 
aqueous humor is diminished, often resulting in heightened intraocular pressure.3  The 
obstruction may be located prior to the iridocorneal angle, within the trabecular 
meshwork, or distal to the meshwork.4 Another clinical feature of primary open angle 
glaucoma (POAG) is the cupping of the optic nerve, which can lead to a corresponding 
loss of vision.3 Critiques of this classification system state that this approach fails to 
account for causes and mechanisms that do not affect intraocular pressure, such as 
genetic factors. Furthermore, there is ambiguity when classifying glaucoma with multiple 
mechanisms of outflow obstruction.4 
Strategies for dealing with POAG are all targeted at controlling IOP by medication or 
surgical interventions.3 Cases of open-angle glaucoma where IOP is not elevated are 
often called normal tension glaucoma (NTG). Estimates of normal tension glaucoma is 
thought to range from 30%-50% of POAG patients.8 NTG is typically characterized by an 
appearance of POAG but diurnal IOP remains < 22 mmHg. 
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2.2.2 Angle Closure Glaucoma 
Angle-closure glaucoma is characterized by the narrowing of, and restriction to, the 
iridocorneal angle, causing diminished aqueous outflow and heightened intraocular 
pressure. One of the most common posterior mechanisms for angle-closure glaucoma is 
pupillary block, where the peripupillary iris is in apposition to the lens and limits the flow 
of aqueous humour from the ciliary bodies into the anterior chamber.9 This causes an 
increase in the pressure within the posterior chamber and a subsequent forward bowing of 
the iris, leading to blockage in the iridocorneal angle. Anterior mechanisms of angle-
closure glaucoma involves a narrowing of the iridocorneal angle as a result of the iris 
being “pulled” into close proximity to the cornea and trabecular meshwork. Angle-
closure glaucoma can also be further classified based on the extent of closure in the 
iridocorneal angle and the pattern of intraocular pressure elevation. Acute angle closure, 
often resulting from total angle closure, may result in a sudden onset of intraocular 
pressure elevation and is accompanied by sudden, severe pain, blurred vision, headaches, 
nausea and other ocular anomalies. Subacute angle closure is defined by sudden increases 
in intraocular pressure which are spontaneously alleviated, which may be symptomatic 
with intermittent headaches. Chronic angle closure occurs when there is permanent 
closure of the anterior chamber angle, however, this type of angle closure is often 
asymptomatic. Most angle-closure glaucoma cases are resolved using laser or surgical 
treatment options. 
2.2.3 Glaucoma Due to Developmental Anomalies 
Incomplete development of structures within the outflow pathway of aqueous humour 
may also lead to glaucoma. Developmental defects such as a high insertion of the anterior 
uvea, incomplete development of the trabecular meshwork and incorrect iridocorneal 
adhesions are clinically recognized defects that are seen in congenital and many other 
forms of glaucoma.4 
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2.3 Epidemiology of Glaucoma 
2.3.1 Prevalence of Glaucoma 
Glaucoma was predicted to affect 60.5 million people worldwide by 2010, increasing to 
79.6 million by 2020 and corresponding to a mean prevalence of 1.96%.10 Angle-closure 
glaucoma is estimated to the leading cause of glaucoma in Asia, however its prevalence 
in North America and Europe is much lower compared to the rest of world, accounting 
for approximately 10% of all glaucoma cases in the United States.9 Several population-
based studies have been conducted in the United States to determine the prevalence of 
glaucoma across various locations, with estimates ranging from 1.97% to 3.69%.11–15 
These studies have revealed that there are significant variations among ethnic and racial 
groups. The Baltimore Eye Survey concluded that the prevalence of glaucoma was 
3.69%, with age-adjusted prevalence rates four to five times higher among the blacks 
compared to whites.11 The differences in the prevalence may be reflective of the varying 
case definitions of glaucoma and differing age distributions within these studies. 
However, these variations may also be indicative of the impact of the large genetic 
heterogeneity within these ethnic groups.4 
In the Canadian context, there is a substantial gap in the literature regarding the 
prevalence of glaucoma.16 Population-based studies have been limited in size and 
geographical location, and are thus limited in the applicability of their results to the 
general Canada populace. A study of 18,000 individuals in the Scarborough, Ontario area 
conducted in 1965 found a glaucoma prevalence of 2.26%.17 Self reported glaucoma 
prevalence derived from national surveys such as the National Population Health Survey 
and the Canadian Community Health Survey was estimated to range from 1.1% to 1.8% 
between 1994-2003, representing a 64% increase in prevalence during this time period.18 
Furthermore, the study showed that the age-specific prevalence of self-reported glaucoma 
increased with age, increasing from a prevalence of 2.7% among adults over the age of 
40 to 10.99% for those over the age of 80.18 The Toronto epidemiology glaucoma survey, 
published in 2011, reported that 7.5% of eligible participants stated they had glaucoma.19 
Furthermore, among participants who reported not having glaucoma who voluntarily 
completed a clinical assessment, 3.9% were diagnosed with glaucoma. However, this 
7 
 
 
 
study was limited in sample size (n = 975) and the author remarked that the proportion of 
eligible participants who volunteered for clinical assessment had higher than average 
family history of glaucoma, which may have contributed to the higher prevalence 
observed.19 In 2007, it was estimated that 24,937 Canadians suffer from severe vision 
loss due to glaucoma, accounting for 3.1% of all vision loss cases in Canada.20 
2.3.2 Risk Factors 
2.3.2.1 Age 
Population studies of glaucoma have demonstrated that the risk is positively correlated 
with age. A meta-analysis of multiple population surveys of prevalence of  open angle 
glaucoma conducted by The Eye Diseases Prevalence Research Group concluded that the 
prevalence increases 10-fold when comparing a group of white adults aged 40-49 and a 
group of adults 80 years old and older.21 Furthermore, results from the Early Manifest 
Glaucoma Trial suggested that being 68 years or older is associated with a 1.47 times 
increase in the risk of developing glaucoma compared to younger persons.22 The positive 
association between age and risk of open-angle glaucoma is evident in other population 
studies conducted in various countries, which concluded that the association is observed 
regardless of race.11,23–25 Current literature speculates that age may be a proxy risk factor 
for currently unassociated causative factors, such as increasing deterioration of ocular 
tissue or social problems such as poor adherence to treatment medication.26 
2.3.2.2 Race 
Primary open angle glaucoma is most prevalent among the Black population, followed by 
the White, Asian and Hispanic populations. The incidence of OAG among Blacks is 
estimated to be two to five times greater than White individuals.27 Furthermore, the Eye 
Disease Prevalence Research Group demonstrated that the prevalence of OAG within 
each age group was higher among the Black population compared to White individuals.21 
Interestingly, conclusions from the Advanced Glaucoma Intervention Study (AGIS) did 
not determine Black race to be a significant risk factor for disease progression.28 While 
this result contradicted findings from other population based studies, it is important to 
note that the AGIS recruited advanced glaucoma patients, which may yield results not 
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directly comparable to other findings. Prevalence of OAG among the Asian population is 
more varied, with southern Asians (from countries in Southeast Asia and India) reflecting 
OAG prevalence similar to the white population, while northern Asians (from China and 
Mongolia) have lower than average OAG prevalence.29 However, the prevalence of angle 
closure glaucoma remains substantively higher among the Asian population.30 
2.3.2.3 Family History 
Family history of OAG is an important predictor for incidence of OAG, particularly if the 
individual is a first-degree relative.31–34 The Baltimore Eye Survey provided evidence 
demonstrating that the association between incidence of glaucoma is stronger between 
siblings (OR 3.7) than when the relative is a parent (OR 2.2) or child (OR 1.1).32 An 
Australian study following 3271 patients in a prospective cohort study determined that a 
family history of glaucoma was associated with a 2.1 times increase in the risk of 
developing glaucoma.5 However, studies that examined the impact of family history 
among patients with established glaucoma did not find a signification association with 
disease progression.22,35 The positive association between family history and risk of OAG 
was also shown in the Barbados Family Study, which was an observational study of the 
families of OAG patients.36 
2.3.2.4 Myopia 
Several studies have supported the association between myopia and the risk of open-
angle glaucoma.37–41 A population study of White Australians showed increasing risk of 
glaucoma with increasing myopia. Individuals with moderate to high myopia (greater 
than -3 D) were reported to have significantly higher risk than lower myopia patients (OR 
3.3).41 Similar results were seen in a study of White Americans, which concluded that 
patients with myopia (greater than – 1 D) were 60% more likely to have glaucoma. 
Furthermore, studies in Asia have demonstrated the association between a high myope 
(greater than -6 D) and the risk of visual field loss due to glaucoma progression.38,39 
Several longitudinal studies have also shown that presence of myopia is associated with 
increasing risk of glaucoma.42–44 
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2.3.2.5 Intraocular Pressure 
There is strong evidence supporting elevated intraocular pressure as a risk factor for the 
development of OAG. Population and longitudinal studies on the prevalence of glaucoma 
have determined that there is a significant dose-response relationship between intraocular 
pressure and disease progression.5,22,45,46 In particular, conclusions from the Ocular 
Hypertension Treatment Study suggests that a reduction of 20% in intraocular pressure is 
associated with a halving of the five year risk of disease development.45 Similarly, the 
European Glaucoma Prevention Study determined that each mmHg increase in IOP, 
sustained for a year, is associated with a 9% increase in the risk of developing open-angle 
glaucoma.47 Results from a randomized clinical trial on the efficacy of glaucoma 
treatments has further demonstrated that control of intraocular pressure resulted in lower 
rates of disease progression compared to participants who had no treatment.45,48,49 
The long term effects of fluctuations in intraocular pressure remain controversial. Studies 
such as the European Glaucoma Prevention Study and the Ocular Hypertension 
Treatment Study have demonstrated long-term intraocular pressure fluctuations not to be 
associated with increased risk of disease progression.47,50,51 On the contrary, results from 
the Advance Glaucoma Intervention Study suggested increased risk of progression with 
fluctuations in intraocular pressure, particularly among those with lower baseline 
intraocular pressure.52,53 Although elevated intraocular pressure is a strong risk factor for 
glaucoma, it is important to note that a significant amount of glaucoma cases are of the 
normal tension variety. Studies on the prevalence of glaucoma estimated that normal 
tension glaucoma accounts for approximately one third of untreated open-angle glaucoma 
patients in the Barbados Eye Study, and up to 85% among untreated Chinese open-angle 
glaucoma patients.54,55 
The only clinically treatable risk factor for glaucoma remains control of and decreasing 
intraocular pressure. To this end, several medication and surgical procedures have been 
utilized in clinical practice. 
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2.4 Cost of Glaucoma 
While many economic analyses have been conducted to determine the cost effectiveness 
of specific medications or surgical techniques used in glaucoma treatment, there is little 
literature on the societal burden of glaucoma. Canadian estimates of the direct healthcare 
cost for treating primary open angle glaucoma ranged from $461 to $697 (in 2001 
Canadian dollars) per patient per year, varying by disease severity.56 However, the study 
estimated cost by assuming total adherence to medication therapy and therefore may 
underestimate the true cost of treatment, as additional treatment costs may be incurred 
due to non-optimal adherence which may lead to accelerated glaucoma progression.56 
Direct healthcare costs estimated from a retrospective chart review of 265 patient yielded 
similar results. Stratified by mean deviation scores, with mild (> -5 decibels), moderate (-
5 to -12 decibels), and advanced (< -12 decibels) glaucoma severity, the estimated direct 
costs ranged from $385 to $460 to $563 (in 2001 Canadian dollars), respectively.57 A 
follow-up study of a smaller subset of 132 patients which included the effects of corneal 
thickness on glaucoma severity determined the cost of disease to range from $406 to 
$432 to $465 when stratified by the same severity levels.58 However, these studies only 
considered medically related costs in the analyses. Hence, societal costs such as hours of 
lost work, lower rates of employment, higher caregiver and supportive device 
requirements were unaccounted for.56–58 
In terms of a health care system level estimate of the burden of illness, a 2002 report by 
Health Canada estimated that $54.7 million (in 1998 Canadian dollars) was spent on 
treating glaucoma.59 Moreover, a recent report conducted for the CNIB and the Canadian 
Ophthalmological Society estimated that the cost of glaucoma to the Canadian healthcare 
system was $549 million (in 2007 Canadian dollars). However, this estimate was based 
on the assumption that the ratio of glaucoma drug expenditure to total drug expenditure is 
the same as glaucoma-related health system expenditure (including medication and other 
direct medical cost) to the total health system expenditure.20 For example, if glaucoma-
related drug expenditure was 3% of total drug expenditure, then the authors assume that 
the glaucoma-related health system expenditure will also be 3% of total health system 
expenditure. This assumption may not hold in practice. For instance, the proportion of 
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hospitalization costs for glaucoma patients compared to patients with other illnesses may 
not be identical to the proportion of drug costs. This is evident in the fact that most 
glaucoma surgical interventions are ambulatory, while other diseases, such as 
cardiovascular disease, require multi-day stays within the hospital. Thus, $549 million 
may be an overestimation of the true burden of illness for glaucoma. 
Similar costs are seen in other countries.60 An American study utilizing insurance claims 
data estimated the direct healthcare burden due to glaucoma to be approximately $2.9 
billion for the US populace (in 2004 US dollars), with the majority of the costs attributed 
to outpatient and pharmaceutical services.61 Furthermore, a review of commercial 
insurance claims in the United States suggested that the average primary open angle 
glaucoma specific costs among its enrollees was $1570, with median cost of $840 (in 
2004 US dollars).62 A retrospective study of primary open angle glaucoma patient records 
concurred with the above results, which demonstrated that the average annual direct 
healthcare costs ranged from $623 to $2511 for patients who are suspected, but not 
diagnosed, of having primary open angle glaucoma and end-stage primary open angle 
glaucoma, respectively.63 The major cost component across all disease severities 
remained medication costs.63 However, like in the Canadian context, these studies only 
examined medication and other direct healthcare costs, and fail to account for indirect 
costs, such as lost productivity by the patient or the caregivers. 
Results from European studies concur with North American findings.64–67 A chart review 
of French and Swedish glaucoma patients revealed that the average annual treatment cost 
per glaucoma  patient to be €390 in France and €531 in Sweden, with approximately half 
of this estimate attributed to the cost of medication (49.6% in France and 48.7% in 
Sweden).64 These estimates were further replicated by a review of patient charts across 
Europe, which demonstrated that healthcare costs range from €455 to €969, depending on 
disease severity. Furthermore, the study concluded that up to 42% to 56% of the direct 
healthcare cost is attributed to cost of medication, depending on the nation of interest.65 
Estimates of the annual healthcare costs, excluding surgery, of late stage glaucoma were 
found to average €830 among France, Denmark, Germany and the United Kingdom. The 
costs increased to €3534 when the estimated cost of paid assistance in the home was 
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included to better approximate the total maintenance cost of disease.66 Based on a review 
of the literature of costs in  several European nations, Poulsen et al. concluded that the 
annual direct healthcare cost per patient to range from €429 to €523, while annual total 
societal cost per patient to range from €11758 to €19111.67 
From these studies, it is evident that the major direct medical cost driver of glaucoma is 
the cost of medication. In order to contain the rapidly increasing healthcare costs, there is 
a strong political and institutional push to support the use of generic medication in 
therapy.68 However, the utilization impact of these cheaper generic antiglaucoma 
medications remains largely unstudied. 
2.5 Medication Therapy in Glaucoma Treatment 
Medication therapy for glaucoma involves the prescriptions of various chemical agents 
aimed at decreasing the pressure within the eye. The mode of action of these medications 
can generally be classified into two categories: medications that 1) improve aqueous 
outflow, usually by increasing drainage of the aqueous humour; or 2) minimize aqueous 
inflow, usually by decreasing production of the aqueous humour. Furthermore, 
medications used in long-term treatment of glaucoma are commonly grouped into 5 
different classes: cholinergic agonists or miotics, α-adrenergic agonists, β-Adrenergic 
receptor antagonists, carbonic anhydrase inhibitors, and prostaglandin analogues.69 
2.5.1 Cholinergic agonists (Miotics) 
The first commercial medication utilized for treatment of glaucoma was pilocarpine 
(Brand name: Isopto Carpine), introduced in the 1870s.69 This drug simulated the effects 
of acetylcholine, stimulating the muscarinic receptors on human ciliary muscle cells. This 
caused the muscles to contract, leading a cascade that results in a change in the structure 
of the trabecular meshwork and an increase in aqueous outflow.70 In ACG patients, it is 
also believed the miotics lower intraocular pressure by relieving the pupillary block.4 
Pilocarpine was the medication of choice for over 75 years before a new type of drug 
appeared. However, as it requires multiple applications per day, utilization of cholinergic 
agonists has dramatically decreased in favour of newer medications that require fewer 
daily applications. 
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2.5.2 α-Adrenergic Agonists 
Epinephrine first became commercially available for glaucoma treatment in the 1950s.71 
Epinephrine acts to decrease intraocular pressure in several ways. Early after 
administration, it elicits a reduction in the production of aqueous humour, however, such 
actions are often transient in nature. After long term administration, it is believed that the 
drug improves aqueous humour outflow.72 Dipivefrin, a modified version of epinephrine, 
was significantly more lipophilic and marketed for its higher corneal penetrability.73 
However, side effects such as systemic hypotension, especially in a paediatric population, 
caused many of the early α-adrenergic agonists to be less favoured as treatment agents.74 
As a result, both dipivefrin and ophthalmic epinephrine are no longer available in the 
Canadian market. 
Since epinephrine and dipivefrin, other more selective α-adrenergic agonists have been 
introduced. Apraclonidine (Brand name: Iopidine) was approved in 1987 by the FDA and 
in 1992 by Health Canada, followed by brimonidine (Brand name: Alphagan) in 1997 by 
Health Canada.75–77 These drugs primarily act to reduce aqueous production, although 
there are studies that suggested that they act to increase outflow and possibly even cause 
increases in prostaglandin levels.4,78,79 Furthermore, as these medications do not exhibit 
the blood-brain barrier penetrability of pilocarpine, it does not elicit the same side effects, 
making it a much more suitable agent for glaucoma management. 
2.5.3 β-Adrenergic Receptor Antagonists (β-blockers) 
The first commercially available β-adrenergic receptor antagonist was propranolol, 
introduced in 1967. Unfortunately, due to severe adverse side effects such as corneal 
anesthesia, it was quickly withdrawn from use.80 A turning point in glaucoma 
management medication came in 1978, when the first timolol maleate (Brand name: 
Timoptic), a non-selective β-adrenergic receptor inhibitor, was approved by the FDA.69 It 
was approved for use by Health Canada the following year.81 Within years of its 
introduction, timolol maleate quickly became the most utilized medication, as it required 
less applications per day and has minimal ocular side effects.69,82 Adrenergic antagonists 
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lower intraocular pressure through the sympathetic system, thereby affecting aqueous 
humour dynamics and decreasing the amount of aqueous humour produced.4,83 
Since the availability of timolol maleate, other β-adrengeric antagonists have been 
developed for glaucoma treatment. Levobunolol (Brand name: Betagan), another non-
selective β-adrengeric antagonist, is an analog of propranolol that was approved by 
Health Canada in 1985.84 Betaxolol hydrochloride (Brand name: Betoptic S), a 
cardioselective, β1-adrengeric antagonist, was approved as an ophthalmic agent in 1994.85 
Levobunolol acts with the same modality as timolol, causing a reduction in aqueous 
production.86 Although other β-adrenergic receptor inhibitors have been approved in 
other nations, these medications have not been introduced to the Canadian market. 
2.5.4 Carbonic Anhydrase Inhibitors 
Acetazolamide (Brand name: Diamox) was approved in 1954 as the first carbonic 
anhydrase inhibitor. First commercialized as an oral preparation, the systemic nature of 
these oral preparations commonly led to widespread, and often unsafe, ocular and 
systemic side effects.87–94 Ocular side effects include transient myopia, blurred vision and 
irritation, and periorbital dermatitis in severe cases.91,93,94 Systemically, carbonic 
anhydrase inhibitors are shown to be associated with side effects such as paresthesia near 
the mouth and in the fingers and toes, metabolic acidosis, gastrointestinal discomfort, and 
in some rare cases, blood dyscrasia.87–90,92 Due to the numerous, and often severe, side 
effects, oral preparations of carbonic anhydrase inhibitors were unfavoured for long-term 
glaucoma treatment. 
The first topical carbonic anhydrase inhibitor, dorzolamide (Brand name: Trusopt) was 
approved by the FDA in 1995 and by Health Canada in the subsequent year.95 While less 
potent than its oral counterparts, dorzolamide had lower occurrences of systemic side 
effects and so is more useful in long-term glaucoma management.96,97 Another carbonic 
anhydrase inhibitor, brinzolamide (Brand name: Azopt), was approved by Health Canada 
in 1998.98 
15 
 
 
 
Carbonic Anhydrase inhibitors lower intraocular pressure by decreasing aqueous 
production through affecting carbonic anhydrase enzymes in the ciliary epithelium. Both 
dorzolamide and brinzolamide inhibit carbonic anhydrase isoenzyme II. Through 
inhibiting the production and transport of bicarbonate into the aqueous chamber, it 
prevents the flow of sodium and water into the chamber, decreasing aqueous 
production.99 Furthermore, some studies have demonstrated that oral carbonic anhydrase 
inhibitors cause metabolic acidosis, a condition known to reduce IOP.87 
2.5.5 Prostaglandins 
Latanoprost (Brand name: Xalatan) was the first prostaglandin analogue approved by the 
FDA in 1996 and Health Canada in 1997.100,101 Several other prostaglandin agents have 
since been approved for clinical use. Unoprostone (Brand name: Rescula) became 
available for use in the USA in 2000 and in Canada since 2006.102,103 Travoprost (Brand 
name: Travatan) was introduced to the US in 2001 and in Canada in 2008. In 2001, 
bimatoprost (Brand name: Lumigan) was approved by the FDA, with approval from 
Health Canada arriving in 2002.104,105 The newest prostaglandin agent, Tafluprost, was 
approved by the FDA in 2012 but has yet to be approved for clinical use in Canada.106 
The prostaglandin hormone is a naturally occurring metabolic product of 20-carbon 
arachidonic acid which has been demonstrated to cause ocular hypertension, 
inflammation and a breakdown of the blood-aqueous barrier when large topical doses are 
given to animal models.107–109 At lower concentrations, the hormone induces ocular 
hypotony and does not cause ocular inflammation, which promoted research and 
development of this drug class into an antiglaucoma agent.110,111 The prostaglandin class 
of medication act on prostanoid receptors distributed throughout the eye.112 
Unfortunately, the precise mechanism by which prostaglandins reduce IOP remains 
unclear. Studies have suggested that the drug works to increase uveoscleral outflow 
through remodelling of the ciliary muscle extracellular matrix.113 Prostaglandins have 
been demonstrated to decrease the amount of collagen molecules in the uveoscleral 
outflow pathways, thereby improving aqueous outflow.114 Due to their need of fewer 
applications and lack of severe side effects, prostaglandins have enjoyed much success 
and have since become the most commonly prescribed medication in glaucoma 
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management and are the recommended first-line therapeutic agent by the Canadian 
Ophthalmologic Society and the American Academy of Ophthalmology.115,116 
The generic medication availability of the medications included in the analyses for this 
study is presented in Figure 2.1. Most of the glaucoma medications in this study have at 
least one generic equivalent available within the Canadian market prior to the 2010 
Ontario Drug System Reform. Cosopt was the only medication in this analysis which had 
its first generic equivalent introduced in 2010. Furthermore, Xalatan, Probeta and 
Xalacom all had their first generic equivalents in the post-reform period (Post-July 2007). 
Epifrin was discontinued by Allergan for distribution in the Canadian market on January 
26, 2010. However, it is important to note that the generic market for antiglaucoma 
medication is volatile and continuously changing. Hence, this study will focus on the 
medications that were available during the study time frame.
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Figure 2.1 Availability of generic equivalents for study medications. Shaded bars indicate the time period during which only the brand name 
compound was available. Unshaded bars indicate the presence of a generic equivalent.  
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2.6 Glaucoma Treatment Paradigm 
Maintenance of visual function and health related quality of life are the overall goals in 
glaucoma management. This is typically achieved through the careful monitoring of 
visual function and providing support for the patient. Should a patient’s glaucoma 
continue to progress, medical interventions may be considered to help the patient achieve 
his or her intraocular pressure targets. The treatment paradigm would differ based on 
numerous considerations and should include a benefit vs. risk analysis alongside the 
patient. 
According to the practice guidelines established by the Canadian Ophthalmological 
Society and the American Academy of Ophthalmology, treatment for glaucoma is 
typically initiated with the use of medication therapy.115,116 Prostaglandins are the most 
effective at controlling intraocular pressure and are associated with fewer systemic side 
effects, and are thus one of the most popular initial eye drops for novel patients. Other 
medications, as highlighted in the above section, could be utilized when cost, side effects, 
intolerance, and patient preferences are considered. Furthermore, multi-medication, or 
combination, therapies may be considered before a patient is referred for alternative 
treatments. 
Laser trabeculoplasty procedures are often considered as an adjunctive therapy to those 
who have failed to control their intraocular pressure using medications. Moreover, there 
is an increasing push to use laser trabeculoplasty as an initial treatment option for 
glaucoma. 
More invasive procedures, such as trabeculectomy or non-penetrating filtration surgeries, 
are often employed only when other methods have been unsuccessful or are likely to be 
unsuccessful at achieving the intraocular pressure targets. In cases where these 
procedures cannot be safely conducted or are unable to produce the desired results, tube 
(aqueous) shunts and cyclodestructive procedures may be considered to control the 
patient’s intraocular pressure. 
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Other procedures done in combination with glaucoma treatments may also be utilized if 
the patient suffered from other visual co-morbidities such as cataracts. 
2.7 Utilization Patterns of Glaucoma Medication 
2.7.1 Database Analyses 
Retrospective studies on the utilization of glaucoma medication have demonstrated close 
associations between the introduction of new antiglaucoma medications and changes in 
the medication utilization patterns. Researchers in a Canadian setting reported similar 
results, with utilization of antiglaucoma medications highly correlated with new entrants 
to the medication market.117–119 A chart review from 3 ophthalmology offices in Alberta 
from 1998-1999 showed that the majority of patients began treatment with β-blockers 
(52%), while only approximately a quarter of patients used prostaglandin as a first-line 
therapeutic agent (27%).118 The authors further studied the use of medication in second-
line therapy, with 34% of patients using a prostaglandin, 32% using a combination of 
prostaglandin and β-blockers, and 20% using other combinations of β-blockers.118 A 
Quebec study examining the utilization of topical antiglaucoma medication among 
glaucoma patients revealed that the majority was prescribed a β-blockers, with over half 
of the patients prescribed timolol (55.3%) and a further 22.4% prescribed betaxolol.117 
Surprisingly, prostaglandin utilization only accounted for 6.6% of total antiglaucoma 
medication prescriptions, however, this could be attributed to fact that prostaglandins 
were restricted as secondary line therapeutic agents prior to the study time frame. Hence 
these medication were not available as a first-line therapeutic agent, which may have 
hindered its utilization in practice.117 A study on the use of combination therapy in British 
Columbia from 2004 to 2007 highlighted that the popular initial class of therapeutic agent 
was prostaglandins (51.78% in 2004 to 56.60% in 2007).119 Interestingly, the study found 
that the second most common utilized class to be combination medications (12.29% in 
2004 to 18.63% in 2007), with β-blockers being the third most commonly used (20.19% 
to 11.56%).119 
In an American context, Stein et al. used data from the Medicare Current Beneficiary 
Survey to determine factors that affect antiglaucoma medication usage. In their analysis 
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of utilization between 1992 and 2002, they demonstrated that the majority of patients 
undergo therapy with β-blockers but utilization of these medications rapidly decreased 
once newer types of medications, such as CAIs and prostaglandins are introduced to the 
market. Carbonic anhydrase inhibitors had the highest level of increased utilization (OR 
1.90 per year), followed by prostaglandin use (OR 1.58 per year).120 A population study 
of Marshland, Wisconsin patients demonstrated that the utilization of all antiglaucoma 
medications beside the prostaglandin class was decreasing from 1985-2005.121 β-blockers 
were the primary prescribed agent from the beginning of the study till 2000, when the 
utilization of prostaglandins overtook use of β-blockers.121 Likewise, a cross-sectional 
review of 100 patient records from 1999 – 2003 in the United States revealed that 
patients who have documented glaucoma were most likely prescribed β-blockers (47%) 
and prostaglandins (44%).122 
Internationally, one of the earliest studies conducted on utilization was within the Nordic 
countries, which concluded that the approval of β-blockers in 1978 quickly led to a 
decrease in the use of cholinergic agonists, and that the use of β-blockers surpassed that  
of cholinergic agonists in 1987.82 Similar trends were seen in other nations. A study of 
antiglaucoma medication utilization between 1995 and 2006 in several European 
countries demonstrated that once introduced, prostaglandins quickly overtook β-blockers 
in utilization. The use of prostaglandins surpassed β-blockers as the primary 
antiglaucoma agent of choice in the UK during 2003, France during 2004 and in 
Germany and Italy during 2005 (estimated).123 A study by De Natale et al. on utilization 
in Italy, which provides free glaucoma drugs to its citizens, demonstrated that from 1997 
to 2002, use of β-blockers dropped significantly from 79% in 1997 to 55% in 2002. 
Meanwhile, use of prostaglandin and carbonic anhydrase inhibitors rose from 0% to 18% 
and 5% to 14%, respectively.124 A study of the prescribing patterns at an Israeli health 
maintenance organization between 2000 and 2003 concluded that while β-blockers had 
the highest prescription rate, their use, along with pilocarpines, were in steady decline.125 
Meanwhile, use of prostaglandin and α-adrenergic agonists increased consistently, and 
the introduction of Cosopt led to a dramatic reversal of the use of dorzolamide.125 In this 
study, the utilization pattern, as determined from drug insurance claims, of antiglaucoma 
medication belonging to the aforementioned drug classes were analyzed. 
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2.7.2 Survey of Clinicians 
The physician’s perspective on medication utilization was also accessed in several 
studies. A survey of Australian and New Zealand ophthalmologists conducted in 2003-
2004 found highly dichotomized results.126 The majority of ophthalmologists from 
Australia preferred prostaglandins as the first line agent of choice (83%), whereas New 
Zealand ophthalmologists preferred β-blockers (90%).126 However this study had a 
relatively low response rate of 51%, and the results may be indicative of the differences 
in government restrictions on the prostaglandin-class medication.126 A 1998 survey of US 
ophthalmologists revealed that the preferred first line agent was a β-blockers (73%) with 
prostaglandins being selected in only 11% of the respondees. This low rate of utilization 
of prostaglandin could be due to the short amount of time between the introduction of the 
first prostaglandin in 1996 and when the study was conducted, thereby limiting the 
amount of time available for physician uptake.127 
2.8 The Pharmaceuticals Market and the Utilization of Generic 
Pharmaceuticals in Canada 
Drug development begins with research and development into novel compounds to 
determine their clinical efficacy and safety profile. Upon discovery of a novel medicinal 
compound, the data are presented to the Therapeutic Products Directorate at Health 
Canada for approval. Once the regulatory requirements are deemed met by Health 
Canada, the company receives a Notice of Compliance for the drug, which allows them to 
market the compound to the Canadian populace. Adoption of the novel drugs into 
publicly funded drug plan formularies remains at the discretion of the province and plan 
managers. Prior to 2003, each public drug plan reviewed the clinical and cost evidence of 
these approved medicines independently to decide on the acceptance of the drug into 
their respective drug plan. In 2003, the Common Drug Review of the Canadian Agency 
for Drugs and Technologies in Health was formed with the goal of creating a system to 
reduce multiple drug reviews and provide a standardized process for evaluating the 
comparative benefits and costs of new drugs. With the goal of providing formulary listing 
recommendations, most provincially funded drug plans, with the exception of Quebec, 
and several federal drug programmes, are currently part of this process.128 Private drug 
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plans hosts their own formularies which may or may not mirror those of the publicly 
funded plans. 
The division between generic and brand name pharmaceutical products in Canada is 
governed by several key pieces of legislation regarding the patent protection of innovator 
(“brand name”) pharmaceutical products. Typically, the patent protects the innovator 
product for a period of 20 years, of which half is usually spent within the research and 
development phase. After the patent expires, drug manufactures are allowed to introduce 
generic equivalents pending evidence of bioequivalence to the Canadian Reference 
Product (the brand name drug) and obtaining approval from Health Canada and 
provincial regulators.129 Like the reference products, inclusions of these generic 
medications into the drug plan formularies are at the discretion of the individual plan 
managers. 
From a healthcare plan perspective, the introduction of generic equivalents is intended to 
provide competition to the innovator medication once the patent protection expires. A 
recent report suggests that within a short period of patent expiration, a multitude of 
interchangeable generic equivalents are available from competitiors.130 To compete in 
this highly competitive field, many generic manufacturers provide rebates to pharmacies 
in exchange for stocking their product. These rebates are essentially kickbacks from 
generics manufacturers paid to pharmacies in exchange for stocking their products, and 
are a substantive portion of the pharmacies’ income (an average rebate was 
approximately equal to 40% of the invoice price).130 However, independent research has 
shown that these savings are not reflected in lower costs to public and private drug plans, 
nor to the patients who pay out of pocket.130,131 
Dispensing of generic medication presents another layer to the unique and complex 
framework for prescribing medication. Provinces can legislate whether to adopt a 
permission product selection rule, where a pharmacy can choose to substitute a 
prescription with an approved generic equivalent. Those against permissive product 
selection have argued that by leaving the choice to the dispensing pharmacist, the 
decision to substitute might not be in the best interest of the patient, but rather substitutes 
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will only be dispensed if there is a positive pay-off for the pharmacy.132 Alternatively, 
provinces can choose to make product selection mandatory, in which prescriptions must 
be substituted with the generic where available unless “No Substitution” is explicitly 
stated by the prescribing physician.132 Furthermore, provincial governments can enact 
price selection rules to contain medication costs. These price selection rules can limit the 
cost reimbursement to pharmacies to that of the generic equivalent, leaving the patient to 
cover the remainder of the cost difference. In Ontario, both mandatory product selection 
and price selections were enacted in July 2010, with mandatory substitution to a generic 
equivalent and fixing prices of generics to a certain percentage of the reference product. 
Recently, provinces across Canada have passed legislation to regulate and reduce the 
price of generic medication. The next section will highlight some of the changes each 
provincial drug plan has implemented. Details regarding the changes to the legislation in 
Ontario with the Transparent Drug System for Patients Act in 2006 and the Ontario Drug 
System Reform in 2010 are presented thereafter. 
2.9 Impact of Pricing Policies on Drug Expenditure and 
Utilization Patterns 
In Ontario, the use of legislation to regulate the price of generic medications began in 
May 1993 with amendments to the Prescription Drug Cost Regulation Act (PDCRA) and 
the Ontario Drug Benefit Act (ODBA).133 These amendments ensured that the maximum 
reimbursement by the Ontario Drug Benefit Program (ODBP) for the first generic drug of 
a brand name product is 75% of the reference price. Subsequent generic products are 
reimbursed only 90% of the first generic price (or 67.5% of the reference price).133 
Further regulation changes in November 1998 to the Drug Interchangeability and 
Dispensing Fee Act (DIDFA, which replaced the PDCRA) lowered the price of the first 
generic equivalent to 70% of the reference price (and therefore subsequent generics to 
63% of the reference price).133 Anis et al., in their evaluation of the impact of these 
reforms on the price of generic medications, concluded that these regulations did not 
decrease the cost of generics as the provincial government had intended.133 Instead, the 
authors found that the introduction of these regulations effectively eliminated the natural 
competition that existed prior to these regulations and eliminated the incentives for newer 
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(subsequent) generic entrants to compete with incumbent generic products with lower 
prices.133 This led to a clustering of generic manufacturers to price their medications 
around the maximum allowable price and reduced potential savings, which were opposite 
of the regulation’s intentions.133 Unfortunately, the impact of these regulations on ODBP 
drug expenditures were not assessed. 
Reference pricing policies in British Columbia have also been studied. Starting in 1995, 
British Columbia implemented its Reference Pricing program for five therapeutic class: 
Nitrates, Angiotensin-converting enzyme inhibitors (ACE inhibitors), Dihydropyridine 
calcium channel blockers (CCBs), Histamine-2 receptor antagonists, and Nonsteroidal 
anti-inflammatory drugs.134 This program aimed to control drug expenditure by fully 
subsidizing the price of the lowest costing drug within each class. Patients who wish to 
receive more expensive drugs will be required to pay for the cost difference, or obtain 
special permission for full subsidy from the government.134 The impact of this policy on 
the drug costs associated with nitrates, ACE inhibitors and CCBs was evaluated by 
Grootendorst et al.135 They concluded that the policy was associated with an annual 
reduction of $7.7 million in the British Columbia Pharmacare program, totalling 
approximately $24 million between October 1995 to May 1999.135 In terms of generic 
utilization changes, the authors noted that there was a significant increase in the use of 
the reference standard product (the generic) with a corresponding decrease in the use of 
restricted (brand name) products.135 
International studies on the impact of pricing regulations on generic drug prices have 
demonstrated similar results, where these pricing regulations on generic drugs have 
stifled competition between generic manufacturers and reduced the potential for drug 
expenditure savings from being realized.136 A review of European pricing policies on 
generic competition found that, like what was observed in Ontario, these policies tend to 
cause generic prices to cluster at the maximum allowed price, which is often higher than 
what would occur in the absence of these policies.137 Interestingly, this review also 
observed that prices of generics already at the reference price will not reduce their prices, 
even if a lower-priced generic is introduced.137 This finding again indicates that the 
presence of reference pricing (and/or price ceiling) policies eliminated price competition 
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between generic manufacturers, as these manufacturers no longer voluntary reduce their 
price in the face of lower-price competition.137 Again, this study resonated with findings 
from other studies in which price ceiling or reference pricing strategies on generic drugs 
are not the optimal method to reduce drug expenditures.137 These policies reduce 
competition among manufacturers, leading to inefficient realization of the benefits of 
competition.137 
Furthermore, most studies conclude that the implementation of reference pricing policies 
is not particularly effective in reducing drug expenditures. Findings by Giuliani in the 
German market showed that the introduction of reference pricing policies did indeed 
cause a short term reduction in expenditures, but that reduction was quickly followed by 
a steady increase.138 Furthermore, the study concluded that the steady increase was a 
result of a growth in the utilization of medications that were not subject to the reference 
pricing policies, such as medications with new active ingredients that the manufacturers 
produce.138 Hence, the introduction of reference pricing in Germany had the opposite 
intended effect due to uncontrolled factors in the pharmaceutical industries.138 Other 
international studies have also determined that the reductions in expenditures due to 
reference pricing policies are short lived in nature.139,140 
Most of these studies evaluated the impact of the introduction of reference pricing or 
price ceiling policies on drug expenditures and generic drug utilization. However, this 
study will focus on evaluating the impact of long term changes in utilization due to these 
policies, in addition to the introduction of said policies. Moreover, many of these studies 
are based on policies that impact only the reimbursement paid by the public drug plan, 
whereas this study is evaluating the impact of a policy that aims to limit both the cost of 
generic drugs in public and private drug plans. 
2.10 Action to Reduce Cost of Generic Medication in Other 
Provinces 
Cost of medication is one of the largest cost components in healthcare expenditure, 
accounting for 15.9% of Canadian health care spending in 2012.141 Expenditures on 
prescription medications increased by an average annual rate of 10.1% between 1998 and 
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2007.142 In 2010, several provinces implemented policies to curb healthcare and drug 
expenditures by restricting the amount reimbursed for generic drugs to ensure that the 
public and private drug plans remain sustainable.143 Quebec made reforms to the amount 
payable for its generic medication effective 2008 with the Loi sur l’assurance 
medicaments (Bill 130), which limits the cost of the first generic of a brand name 
medication to 60% of the brand name price, and subsequent generics to 54% of the brand 
name price. Further announcements were made in November 2010 to reduce prices of 
generics to 25% of the brand name over three years, beginning with a decrease to 37.5% 
in November 2010, reducing to 30% by April 2011 and finally 25% by April 2012. 
Moreover, Quebec also has a “Most-Favoured-Nation” legislation, which requires that 
the sales prices of generic medication within Quebec match the lowest paid in Canada, 
hence essentially matching Ontario’s pricing scheme. 
British Columbia enacted policies in July 2010 to reduce reimbursement for all generic 
medication introduced after January 1, 2009 to 42% of the brand name equivalent, while 
reimbursement for existing generics introduced prior to January 1, 2009 remained at 50% 
of the brand equivalent. Further reductions saw the maximum reimbursement lowered to 
40% in July 4, 2011, and to 35% in April 2, 2012.144 
Similar plans were adopted by Nova Scotia with its “Fair Drug Pricing Act”, which 
reduced the prices of generic medication paid by its public drug plan to 45% of the brand 
name equivalent by July 2011, decreasing to 35% by July 2012.145 Saskatchewan 
followed suit by lowering existing generic medication prices to 45% of the brand name 
price by June 1, 2011, lowering to 35% by April 1, 2012. Generic drugs introduced after 
May 4, 2011 will be priced at 40% of the brand name equivalent, dropping to 35% by 
April 1, 2012.146 
Alberta reduced the price of existing generics as of April 1, 2010 from 75% to 65% of the 
brand name equivalent. New generics introduced into the market will be priced at 45% of 
the brand name drug. Prices of all generics were further reduced to 35% of their brand 
name equivalents effective July 1, 2012. Further reductions were enacted in its 2013 
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budget, where the Alberta government is again lowering reimbursement for generic 
medication to 18% of the brand equivalent.147 
New Brunswick has also introduced legislation to address the rising cost of medication 
within its public drug program. The New Brunswick government announced on March 
22, 2012 that it will reduce the price of the generic medication to 40% of the brand name 
drug, effective June 1, 2012. Further reductions were made to lower this price to 35% of 
the brand price by December 1, 2012.148 
In order to address the impact on pharmacy revenues due to the decrease in generic drug 
prices, many of the provinces have made changes to the alternative sources of revenue for 
pharmacies. Most of these price reductions are accompanied with legislation which 
increases the dispensing fees that pharmacies are eligible to charge. Other provinces 
allow allowances to be billed in addition to medication and dispensing fees, but these are 
subject to phasing out over time. 
2.11 Ontario Drug System Reforms 
The drug system reform was initiated by the Ontario government in an effort to reduce 
public expenditure on the provincial drug plan. In 2006, the Ontario government enacted 
the Transparent Drug System for Patients Act (Bill 102) to reduce the cost paid by the 
Ontario Drug Benefit program for generic medication to 50% of the brand reference 
price. Maximum markup for drugs dispensed to patients covered by the public drug plan 
was also decreased from 10% to 8%. Furthermore, the act prohibits the payment of 
rebates to pharmacies by the generic manufacturers. To compensate the pharmacies, 
professional allowances were introduced. These allowances enable generic manufacturers 
to pay pharmacies up to 20% of invoice price for drugs dispensed under the public drug 
plan to stock their product and offset the cost of providing non-dispensing activities such 
as advising patients or hosting flu clinics. Dispensing fees were also increased from $6.54 
to $7.00 for publicly funded prescriptions. However, price ceiling, markup and 
dispensing fees for privately funded patients or patients who pay out of pocket remain 
unregulated.149 Bill 102 also included amendments to the Drug Interchangeability and 
Dispensing Fees Act, an act that permits pharmacists to interchange a patient’s 
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prescriptions for brand name medication with interchangeables approved by the Ontario 
government. Bill 102 introduced changes to  widen the definition of interchangeables to 
include products that have “similar active ingredients in a similar dosage form” as the 
reference product.150 
The government made further amendments to the ODBA and the DIDFA, effective on 
July 1, 2010, to further reduce the cost of medication on the public drug program.151 In 
essence, the amendments had three goals. (i) Reduction of the cost of generic drugs 
dispensed to Ontario Drug Benefit beneficiaries to 25% of the brand reference price. 
Prices paid by private insurance and non-insured patients, which were previously 
unrestricted, will be initially capped at 50% of the brand reference price, to 35% effective 
April 1, 2011, and finally to 25% to match the public sector by April 1, 2012. One 
exception to this price ceiling is for the non-solid dosage interchangeable drugs, which 
will be capped at the 35% of the brand reference price. (ii) Professional allowances, 
which are funds paid by generic medication manufacturers to pharmacies to stock their 
medications and for patient-focused activities, will be eliminated in the public sector. 
Caps on the professional allowances for the private sector will fall from 50%, to 35% and 
25% of the allowances paid prior to the reform, mirroring the price drop in drug costs. 
Professional allowances for the private market will be completely eliminated by April 
2013, following amendments to the DIDFA. (iii) Dispensing fees charged by pharmacies 
for the public sector were adjusted based on their location and proximity to other 
pharmacies in the area. Fees were stratified into four categories to replace the current 
single fee model, with more rural and underserved pharmacies eligible for higher 
dispensing fees. Prices, allowances and dispensing fees for generic drugs that are not 
listed on the Ontario Drug Benefit Formulary remains to be unregulated.152–156 
2.12 Studies on the Impact of the Transparent Drug System for 
Patients Act and the 2010 Ontario Drug System Reform 
There has been minimal research on the impact of Transparent Drug System for Patients 
Act on the cost and utilization of drugs in Ontario. One thesis examined the effects of the 
introduction of the Bill 102 on the out-of-pocket drug expenditure for patients who are 
not covered by public drug plans (private patients).157 The thesis concluded that the 
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introduction of the Bill was associated with an 18% increase in the out-of-pocket drug 
expenditure when comparing Ontario private patients to those in provinces that did not 
implement a similar act.157 Furthermore, the study determined that the Bill increased the 
propensity for Ontario private patients to suffer from drugs expenditures greater than 5% 
of its household income.157 
Little research evaluating the impact of the 2010 Ontario Drug System Reform on the 
cost of healthcare in Ontario has been published. In one study, Law et al. determined that 
the legislation and implementation of the policy reform has led to a 6 month cost savings 
of $181 to $194 million to the Ontario public drug program in post-legislation 2010, 
accounting for dispensing fees. Furthermore, the study predicted that that the annual total 
cost savings to the Canadian healthcare system to be approximately $1.28 billion if other 
provinces adopt similar reimbursement schemes as Ontario.158 Industry reports of the 
impact of the system reform estimated a reduction of 13.8% in average generic drug cost, 
which represents a savings of 2.55% in the total drug plan costs. Accounting for the 
increases in dispensing fee and in pharmacy mark-up, the net savings of the system 
reform is estimated to be 2% of the total drug plan costs.159 
2.13 Summary of the Gaps in the Literature 
Policies that encourage generic substitution and decrease the reimbursement scheme for 
generic medication have been demonstrated to decrease total drug expenditure and 
increase the utilization of generic drugs.134,135,139,160–163 However, whether the adoption of 
similar policies, namely the 2006 Transparent Drug System for Patients Act and the 2010 
Ontario Drug System Reform, has a similar effect on the utilization of generic medication 
among Ontario patients remains unknown. As demonstrated in this chapter, the literature 
evaluating the impact of the two drug system reforms in Ontario during 2006 and 2010 is 
sparse. The few studies that have examined the impact of these reforms have focused 
primarily on the changes in drug expenditure at a provincial level, or the changes within 
Ontario patients who are not covered by public insurance. In terms of provincial drug 
expenditure, studies have demonstrated that these reforms have been associated with a 
decrease in the drug costs.158 Furthermore, changes to the price ceilings implemented by 
the provincial government have been found to increase the drug expenditures of patients 
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who pay out-of-pocket for their medications.157 In addition, there is a lack of literature on 
the utilization of generic medication within the glaucoma market, particularly in a 
Canadian setting. 
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Chapter 3  
3 Study Rationale and Objectives 
In the previous chapter, a comprehensive literature review was presented. It demonstrated 
that studies on the utilization patterns of generic medication glaucoma therapy in Canada 
and worldwide are scant. Furthermore, although there is one study and several industry 
reports evaluating the impact of the 2010 Drug System Reform on the cost of prescription 
medication in Ontario, none have empirically analyzed the change in generic equivalent 
utilization since the reform. Hence, in this study, we propose objectives to address both 
these gaps in the literature to meaningfully contribute to the body of knowledge of the 
use of generic antiglaucoma medication in Canada and to empirically demonstrate the 
impact of generic drug price ceiling reforms on utilization and drug expenditure. 
3.1 Study Objectives 
The objectives of this thesis are: 
1. Describe the trend of existing generic utilization in antiglaucoma medication 
across Canadian provinces between January 2001 and January 2013.  
Rationale: Such a study will reveal the level of utilization of generic medication within 
glaucoma treatment. As medication costs remain the highest cost component in glaucoma 
treatment, results of this study can determine whether programs and policies are needed 
to increase the level of generic utilization to decrease the drug expenditures of Canadian 
glaucoma patients. 
2. Assess the impact of the 2010 Ontario Drug System Reform on generic 
antiglaucoma drug utilization and expenditure in Ontario.  
Rationale: Results of this study will provide empirical evidence of the impact of the 
adjustment to generic drug price ceiling on the utilization of these drugs. Demonstrating 
the effectiveness (or lack thereof) of the price-ceiling reform on increasing utilization and 
decreasing expenditures may guide policy-makers in introducing appropriate methods to 
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promote the use of the generic drug use in lowering rising drug costs. Furthermore, 
understanding the response in drug utilization and drug expenditure can inform policy-
makers when preparing future modifications to the drug system. Lastly, the findings may 
be of interest to foreign policy-makers who are planning to introduce price ceilings on 
prescription medication to contain rising healthcare costs across the globe. 
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Chapter 4  
4 Methods 
4.1 Study Design 
The study design was a descriptive study of the use of generic medication in glaucoma 
treatment across various Canadian provinces between January 2001 and January 2013. 
The trends in the volume of medications dispensed, percentage of medication dispensed 
as a generic equivalent, and the generic medication utilization rate will be described 
through the study timeframe. This study stratified the analyses by claims made to public 
and private health insurance. 
A time series analysis was also conducted to determine the impact of the 2010 Ontario 
Drug System Reform on generic antiglaucoma medication utilization among Ontario 
glaucoma patients. The analysis was conducted using an autoregressive integrated 
moving average (ARIMA) model to ascertain whether the observed utilization rate post-
reform is congruent with predictions made from pre-policy trends. 
4.2 Medications Used in Glaucoma Treatment 
Medications in the drug classes presented in the literature review were considered as 
agents used in glaucoma treatment. For this study, only ophthalmic solutions or topical 
gellan preparations were examined, with solid tablet formulations excluded. Only non-
solid formulations were included in the analyses as the drug reform has enacted a 
different pricing structure towards non-solid formulation medications. Thus an analysis 
of both solid and non-solid formulation antiglaucoma medication may mask the effect of 
the policy on utilization of these medications. Estimates derived from the dataset show 
that solid formulation medications accounts for 1.6% to 8.1% and 1.2% to 2.9% for 
private and public insured claims, respectively, across the study provinces. Hence, due to 
the small market share of solid formulations in the antiglaucoma drug market, the impact 
of these medications on the generalizability of the study results to all antiglaucoma 
medication is limited. 
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All antiglaucoma medications that were available from January 2001 to January 2013 
were included in the analysis. A comprehensive list of the medication with the drug class, 
trade name, drug identification number, manufacturer, and dosage strength are presented 
in Table 4.1. Please note that the availability of medication may differ among provinces. 
Table 4.1 List of Study Medication 
Therapeutic Agent 
/ Drug Class Trade Name 
Drug 
Identification 
Number Manufacturer 
Dosage 
Strength 
Adrenergic Agonists Epifrin 1090 Allergan 0.5% 
Adrenergic Agonists Propine * 529117 Allergan 0.1% 
Adrenergic Agonists Iopidine 888354 Alcon Canada 1% 
Adrenergic Agonists Ratio-Dipivefrin * 2032376 Teva Canada Ltd 0.1% 
Adrenergic Agonists Iopidine * 2076306 Alcon Canada 0.5% 
Adrenergic Agonists Dpe * 2152525 Alcon Canada 0.1% 
Adrenergic Agonists Probeta * 2209071 Allergan 0.5% 
Adrenergic Agonists Alphagan * 2236876 Allergan 0.2% 
Adrenergic Agonists Pms-Dipivefrin * 2237868 Pharmascience 0.1% 
Adrenergic Agonists Apo-Dipivefrin * 2242232 Apotex Inc 0.1% 
Adrenergic Agonists Ratio-Brimonidine * 2243026 Teva Canada Ltd 0.2% 
Adrenergic Agonists Pms-Brimonidine * 2246284 Pharmascience 0.2% 
Adrenergic Agonists Alphagan P * 2248151 Allergan 0.15% 
Adrenergic Agonists Apo-Brimonidine * 2260077 Apotex Inc 0.2% 
Adrenergic Agonists Apo-Brimonidine P * 2301334 Apotex Inc 0.15% 
Adrenergic Agonists Sandoz-Brimonidine * 2305429 
Sandoz Canada 
Inc 0.2% 
Beta Blocking 
Agents Timoptic * 451193 
Merck Canada 
Inc 0.25% 
Beta Blocking 
Agents Timoptic * 451207 
Merck Canada 
Inc 0.5% 
Beta Blocking 
Agents Betagan * 637661 Allergan 0.5% 
Beta Blocking 
Agents Betoptic 695688 Alcon Canada 0.5% 
Beta Blocking 
Agents Betagan * 751286 Allergan 0.25% 
Beta Blocking 
Agents Apo-Timop * 755826 Apotex Inc 0.25% 
Beta Blocking 
Agents Apo-Timop * 755834 Apotex Inc 0.5% 
Beta Blocking 
Agents Mylan-Timolol * 893773 Mylan Pharma 0.25% 
Beta Blocking 
Agents Mylan-Timolol * 893781 Mylan Pharma 0.5% 
Beta Blocking 
Agents Betoptic S * 1908448 Alcon Canada 0.25% 
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Beta Blocking 
Agents Ratio-Levobunolol * 2031159 Teva Canada Ltd 0.25% 
Beta Blocking 
Agents Ratio-Levobunolol * 2031167 Teva Canada Ltd 0.5% 
Beta Blocking 
Agents Teva-Timolol * 2048515 Teva Canada Ltd 0.5% 
Beta Blocking 
Agents Teva-Timolol * 2048523 Teva Canada Ltd 0.25% 
Beta Blocking 
Agents Pms-Timolol * 2083345 Pharmascience 0.5% 
Beta Blocking 
Agents Pms-Timolol * 2083353 Pharmascience 0.25% 
Beta Blocking 
Agents Sandoz-Timolol * 2166712 
Sandoz Canada 
Inc 0.25% 
Beta Blocking 
Agents Sandoz-Timolol * 2166720 
Sandoz Canada 
Inc 0.5% 
Beta Blocking 
Agents Timoptic-Xe * 2171880 
Merck Canada 
Inc 0.25% 
Beta Blocking 
Agents Timoptic-Xe * 2171899 
Merck Canada 
Inc 0.5% 
Beta Blocking 
Agents Novo-Levobunolol 2197456 Teva Canada Ltd 0.25% 
Beta Blocking 
Agents Novo-Levobunolol 2197464 Teva Canada Ltd 0.5% 
Beta Blocking 
Agents Levobunolol * 2231714 Rivex Pharma 0.25% 
Beta Blocking 
Agents Levobunolol * 2231715 Rivex Pharma 0.5% 
Beta Blocking 
Agents Sandoz-Betaxolol 2235971 
Sandoz Canada 
Inc 0.5% 
Beta Blocking 
Agents Pms-Levobunolol * 2237991 Pharmascience 0.5% 
Beta Blocking 
Agents Dom-Timolol 2238771 
Dominion 
Pharmacal 0.5% 
Beta Blocking 
Agents Ratio-Timolol 2240248 Teva Canada Ltd 0.25% 
Beta Blocking 
Agents Ratio-Timolol * 2240249 Teva Canada Ltd 0.5% 
Beta Blocking 
Agents Apo-Levobunolol * 2241574 Apotex Inc 0.5% 
Beta Blocking 
Agents Apo-Levobunolol * 2241575 Apotex Inc 0.25% 
Beta Blocking 
Agents Sandoz-Levobunolol * 2241715 
Sandoz Canada 
Inc 0.25% 
Beta Blocking 
Agents Sandoz-Levobunolol * 2241716 
Sandoz Canada 
Inc 0.5% 
Beta Blocking 
Agents Sandoz-Timolol 2241731 
Sandoz Canada 
Inc 0.25% 
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Beta Blocking 
Agents Sandoz-Timolol 2241732 
Sandoz Canada 
Inc 0.5% 
Beta Blocking 
Agents Timolol Maleate-Ex * 2242275 Alcon Canada 0.25% 
Beta Blocking 
Agents Timolol Maleate-Ex * 2242276 Alcon Canada 0.5% 
Beta Blocking 
Agents Combigan * 2248347 Allergan 0.2/0.5% 
Beta Blocking 
Agents Duotrav * 2278251 Alcon Canada 0.004/0.5% 
Beta Blocking 
Agents Apo-Timop Gel * 2290812 Apotex Inc 0.5% 
Beta Blocking 
Agents Azarga * 2331624 Alcon Canada 1%/0.5% 
Beta Blocking 
Agents Combigan * 9857298 Allergan 0.2/0.5% 
Beta Blocking 
Agents Duotrav * 9857333 Alcon Canada 0.004/0.5% 
Carbonic Anhydrase 
Inhibitors Trusopt * 2216205 
Merck Canada 
Inc 2% 
Carbonic Anhydrase 
Inhibitors Azopt * 2238873 Alcon Canada 1% 
Carbonic Anhydrase 
Inhibitors Cosopt * 2240113 
Merck Canada 
Inc 2/0.5% 
Carbonic Anhydrase 
Inhibitors Cosopt * 2258692 
Merck Canada 
Inc 2/0.5% 
Carbonic Anhydrase 
Inhibitors Trusopt 2269090 
Merck Canada 
Inc 2% 
Carbonic Anhydrase 
Inhibitors Apo-Dorzo/Timop * 2299615 Apotex Inc 20mg 
Carbonic Anhydrase 
Inhibitors Sandoz-Dorzolamide 2316307 
Sandoz Canada 
Inc 2% 
Carbonic Anhydrase 
Inhibitors Sandoz-Dorzol/Timol 2344351 
Sandoz Canada 
Inc 2%/.5% 
Prostaglandin 
Analogs Xalatan * 2231493 Pfizer 0.005% 
Prostaglandin 
Analogs Travatan * 2244896 Alcon Canada 0.004% 
Prostaglandin 
Analogs Xalacom * 2246619 Pfizer 0.005% 
Prostaglandin 
Analogs Co Latanoprost * 2254786 Cobalt Pharma 0.05mg/ml 
Prostaglandin 
Analogs Apo-Latanoprost * 2296527 Apotex Inc 50mcg/ml 
Prostaglandin 
Analogs Travatan Z * 2318008 Alcon Canada 0.004% 
Prostaglandin 
Analogs Sandoz-Latanoprost * 2367335 
Sandoz Canada 
Inc 50mcg/ml 
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Prostaglandin 
Analogs Gd-Latanoprost * 2373041 Genmed 50mcg 
Prostaglandin 
Analogs Travatan Z * 9857332 Alcon Canada 0.004% 
2324997 
9857368 
Prostaglandin 
Analogs 
Lumigan* 
9857398 
Allergan 0.01% 
* Denotes drugs which are available on the Ontario Drug Benefit Formulary  
4.3 Dataset Description 
Medication dispensing claims were used as a proxy to estimate the utilization of 
antiglaucoma medication among Canadian patients. This study utilized data from the 
PharmaStat database supplied by IMS Brogan, a division of IMS Health Canada.164 IMS 
Brogan maintains a variety of healthcare related databases, including the PharmaStat and 
CompuScript databases which are used extensively in pharmacoepidemiological 
research.165–172 Studies utilizing these databases are focused on examining the change in 
utilization of medication over time, cost changes in dispensing over time, or on the 
impact of policies on drug use. The CompuScript database was used by Fischer et al. in 
their evaluation of the trends in opioid use and to determine the impact of prescription 
monitoring programs on the utilization of opioids in 10 Canadian provinces.167 The 
dataset enabled the authors to determine there were significant differences in the level of 
opioid dispensed between the provinces.167 Furthermore, they concluded that there was 
an increase in the level of opioids dispensed, and that this increase is driven 
predominately by an increases in “strong opioid” use.167 The CompuScript database was 
also utilized by Law et al. in their analysis of the impact of the 2010 Ontario Drug 
System Reform on public drug expenditure.166 They concluded that the reform was 
associated with a decrease in drug expenditure of approximately $181 to $194 million in 
the 6 months after the reform was introduced.166 Data derived from CompuScript have 
also be used to determine the impact of the introduction of OxyContin-OP in the US on 
prescribing patterns of OxyContin in Canada and in evaluating the cost of self-monitoring 
of blood glucose in diabetes management among Canadian diabetics.165,168 The 
PharmaStat database has been used in studies examining the cost of osteoporosis in 
Canada and used in drawing comparisons of the utilization of prescription medication 
between different areas in Canada.169,170,173 Moreover, it has been used to quantify the 
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effect of the Common Drug Review on the adoption of new drugs by various provincial 
jurisdictions.128 More recently, it has been used to evaluate the impact of generic drug 
entry on private drug plan expenditures.174 Its extensive use in drug utilization and 
expenditure research is indicative of the quality and reliability of the PharmaStat 
database. 
The PharmaStat database aggregates Canadian drug plan reimbursement data from a 
sampling frame of approximately 5600 pharmacies across Canada. Retail sales from this 
sampling frame are then projected to provide Canada-wide and province-specific sales 
estimates. The database reports total formulary sales for most public drug plans, 
including claims from provincial drug benefit programs and federal Non-Insured Health 
Benefit (NIHB) programs. Furthermore, it reports the direct payments from private 
insurance plans to pharmacies, providing coverage of 67% of all private prescriptions in 
Canada.175 In Ontario, the coverage of private drug plan exceeds 80%. The database 
yields key information such as the name of the drug, name of the active chemical agent, 
type of drug, formulation, the drug identification number (DIN), manufacturer, generic 
status. Outcomes obtained from the database include the volume of claims, the number of 
units sold, and the total cost of the claims. In this study, the volume of claims was used to 
determine the utilization of antiglaucoma medication. 
Examples of how claims are recorded in the database are presented in Table 4.2. 
Table 4.2 Examples of Claims Records 
Patient Prescription Number of visits to the 
pharmacy in one year 
Number of yearly claims 
within the database 
A Timolol for 365 days 1 1 
B Initial Timolol for 90 
days, with 3 refills 
4 4 
C Initial Timolol for 120 
days, with 2 refills 
3 3 
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4.4 Independent Variables 
4.4.1 Generic Status 
Study medications were further stratified into two groups for all analyses. The first group 
consisted of brand name medications. The second group consisted of medications deemed 
as generics. Generic status of these medications was derived from the IMS PharmaStat 
database. 
To ascertain that the generic status of the study medications was correctly identified in 
the PharmaStat databases, the recorded status was validated by comparing the drug name, 
drug identification number (or its equivalent in other provinces) against the records 
within their respective provincial drug benefit formulary. Drugs which were classified as 
an interchangeable within the formulary for a brand name product were considered as a 
generic. The drug name was also compared with the Notice of Compliance database 
maintained by Health Canada to identify subsequent entry (generic) status.176 
4.4.2 Time 
In the descriptive analysis, time provided the scale by which the outcome measures are 
plotted. For the time series analysis, the outcome measures were stratified into two 
groups. The first category included outcome measures that are from the time period prior 
to the 2010 Ontario Drug System Reform. The second category included outcome 
measures that are from the post reform time period. The impact of the 2010 Ontario Drug 
System Reform was evaluated through comparisons of these two groups. 
4.4.3 Drug Insurance Status 
The outcome measures were divided into two categories, with analyses conducted 
separately for each category. The first category included publicly insured cost and claims. 
The second category included privately insured cost and claims. 
4.5 Outcome Measures 
Four outcome measures were constructed to represent the use of generic antiglaucoma 
medication. First, analyses were conducted using the monthly volume of claims of 
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generic antiglaucoma medication to provide a crude representation of the utilization of 
generic drugs. 
Second, a monthly generic percentage dispensed was constructed to model the utilization. 
This construct was defined by summing the monthly prescriptions filled for generic 
antiglaucoma equivalents; the sum was then divided by the total volume of both generic 
and branded prescriptions of antiglaucoma medication filled within the month and 
expressed as a percentage. 
Third, a monthly dispensing rate of generic medication was constructed by dividing the 
monthly number of claims for generics by the estimated monthly population for each 
province studied. The monthly population was estimated for the study time frame of 
2001-2013 from the CANSIM database maintained by Statistics Canada.177 The 
CANSIM database reports on a wide variety of socioeconomic variables, ranging from 
population demographics, labour, finance, to travel and tourism. In particular, this study 
made use of the population estimates and projections tables which provided annual 
estimates of the population size, stratified by age group and sex, for July 1st across 
provinces and territories.178 Monthly estimates of the provincial population size was 
determined by fitting a trend line to the annual estimates from 2000-2012 and the 
equation was used to interpolate the monthly values. The monthly dispensing rate of 
generic antiglaucoma medication for each province was determined by dividing the 
monthly dispensing volume of generic antiglaucoma medication by the corresponding 
estimated monthly population size. This measure was expressed as the dispensing rate per 
100,000 residents per month. 
Lastly, the monthly total cost of all insured claims for antiglaucoma medication was 
estimated by summing the cost associated with each medication under examination. 
The monthly dispensing volume of generic antiglaucoma, estimated population size in 
Ontario per month, the monthly generic percentage dispensed, the monthly dispensing 
rate, and the monthly total cost of medication were captured in an Excel database for 
conversion to a SAS dataset (SAS, version 9.3, Cary NC). 
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4.6 Data Analyses 
4.6.1 Descriptive Analysis 
The monthly volume of generic claims, the monthly generic percentage dispensed, the 
monthly dispensing rate of generic equivalents, and the monthly total cost of 
antiglaucoma medications were plotted by provinces and over the study time frame to 
provide a visual description of the use of generic antiglaucoma medication. This analysis 
was further stratified by publicly insured claims and privately insured claims and 
included the medications listed in Table 4.1. 
4.6.2 Time Series Analysis 
A time series is a set of ordered observations which have been sampled over discrete, 
equally spaced and neighbouring time intervals.179 As a result, time series data have 
increased likelihood to be correlated which presents a unique problem during analysis.179 
An assumption in many classical statistical analyses, such as regression analysis, requires 
that the data be independent and identically distributed. This assumption is often violated 
when used with time series data due to the high level of autocorrelation among nearby 
observations. Time series analysis are modified methods to modelling the data by taking 
into account the autocorrelation into the analyses, often by including prior observations 
of the dependent variable as explanatory variables in a type of regression model.180 
Autoregressive integrated moving average (ARIMA) models is a class of time series 
modelling technique which accounts for the “noise” generated by the autocorrelation 
within the data.181 Once the “noise”, such as trends and seasonality, are adjusted for, the 
impact of an exogenous intervention can be determined with the inclusion of an 
intervention component into the ARIMA model.181 
In particular, a seasonal, interventional ARIMA model developed using data from 
January 2001 to January 2013 was used to estimate the effect of the policy introduction. 
This model allowed for the quantification of the reform’s impact on the monthly volume 
of generic claims, monthly generic percentage dispensed, the monthly dispensing rate of 
generic equivalents, and the monthly total cost of antiglaucoma medications. The 
ARIMA modelling technique was first developed within the field of econometrics and 
43 
 
 
 
was used for the forecasting of financial data, but has since been adopted for use in 
healthcare research.182–186 It has since been utilized in studies which evaluate the impact 
of publications and policy change on practice and prescribing patterns and other health-
related outcomes.187–190 
The use of time series methods requires the data to be stationary, meaning the data has a 
constant mean and variance across all time points. This requirement was assessed using 
the augmented Dickey-Fuller test and the correlogram, which provides information on the 
autocorrelation, partial autocorrelation, and inverse autocorrelation. Differencing between 
lags was introduced into the model as necessary to maintain the stationary property. 
Various permutations of the ARIMA model parameters were tested beginning with the 
least parsimonious, lowest order model. The Ljung-Box χ2 statistic  was calculated to 
assess the autocorrelation between lags and to measure whether the calculated residuals 
were uncorrelated white noise.191 The optimal combination of the orders of 
autoregressive (AR) and moving average (MA) was selected by assessment of the 
correlogram and the autocorrelations. Maximum likelihood methods were used for 
estimation of the model parameters.192 The use of maximum likelihood for estimation 
generally results in better estimates than using exact least squares or conditional least 
squares methods.193 All p-values were two-sided. 
In this study, the 2010 Ontario Drug System Reform was modelled as the intervention 
event. The effect of this reform on utilization of generic antiglaucoma medication was 
assessed by inclusion of an intervention parameter. In a sensitivity analysis, the 2006 
Transparent Drug System for Patients Act was also introduced as an intervention to 
evaluate the effect of both drug reforms on generic utilization trends. Ramp, point, and 
step functions were utilized to incorporate the intervention parameter into the model. 
Ramp functions are utilized to describe situations when an intervention causes the linear 
trend to change slope. Step interventions cause a permanent change in the level of the 
output variable. A point or pulse function is similar to a step function, but elicits a 
temporary change in the level of the output variable. The level of the output variable may 
return to its original state once the point intervention has concluded.182 Studies have 
utilized a ramp function to model the effect of the introduction of new legislation or 
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health advisories on various health-related outcomes.184,188–190,194 Step functions are also 
utilized in research to model the impact of interventions such as prevention programmes 
and policy changes.195–197 
The use of a ramp function may be the most appropriate given that there may be a lag 
time between the introduction of the reform and a change in physician prescribing 
patterns. Furthermore, a pharmacy may not change its dispensing practices until current 
stock of medications is sold. However, as a sensitivity analysis, all three types of 
interventions functions will be assessed in the analysis. 
Subsequent analyses were conducted to evaluate the impact of both the 2006 Transparent 
Drug System for Patients Act and the 2010 Ontario Drug System Reform on the 
aforementioned outcome measures. Both reforms were included in the analyses through 
the use of an intervention parameter introduced by a ramp function. 
The β estimate of the intervention parameters were examined to determine the statistical 
significance of the impact of the intervention. Two-sided p-values were calculated with 
statistical significance defined as p < 0.05. Two models for each outcome measure were 
constructed to evaluate the impact of the drug system reform on utilization among 
publicly insured patients and privately insured patients. Identification of the model 
parameters for the order of correlation, order of integration and order of moving average, 
and model estimates were conducted using SAS 9.3 and SAS/ETS 9.3 (SAS Institute, 
Cary, NC). 
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Chapter 5  
5 Results 
5.1 Data Availability  
Monthly dispensing claims were obtained from the PharmaStat database for Alberta, 
Manitoba, Ontario, Quebec, New Brunswick, Nova Scotia, and Newfoundland. 
Dispensing claims for privately insured prescriptions over all 145 months from January 
2001 to January 2013 were available for the provinces in this study. Data for 
prescriptions covered by public drug plans were staggered in availability, with only 
Alberta and Ontario having claims available from January 2001 to January 2013. A full 
list of the availability for dispensing claims is presented in Figure 5.1. 
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Alberta
Manitoba
Ontario
Quebec
New Brunswick
Nova Scotia
Newfoundland
Availability of Publicly Insured Dispensing Claims
 
Figure 5.1 Availability of Dispensing Claims. 
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5.2 Results of the Generic Status Validation 
Generic status indicators from IMS Brogan were mostly correct for the medications 
included in this study. One error was found for Timolol Maleate-EX (Manufacturer: 
Alcon Canada; DIN: 02242275, 02242276). Entries for Timolol Maleate-EX were 
reclassified as a generic product for all analyses. 
5.3 Descriptive Results 
5.3.1 Volume of Generic Claims 
The monthly dispensing volume of generic medications across the study provinces are 
presented in Figures 5.2 and 5.3 for publicly and privately insured claims, respectively. 
From January 2001 to January 2013, the volume of generic antiglaucoma medications 
dispensed among insured claims increased across all provinces. As expected, the largest 
increases in the volume of claims were found within the provinces with the largest 
populations, Ontario and Quebec, across both public and privately insured claims. 
Annual fluctuations in the volume of publicly insured claims were observed over the 
study time frame across all study provinces. In Ontario, considerable fluctuations were 
seen over the study time frame. A large decrease in volume of generic claims was 
observed during 2002; however this decrease was mitigated by a substantive increase 
during 2003. In the same year, the volume of generic claims began to fall, and this 
decrease continued till 2006, at which point it quickly rebounded to over 20,000 claims 
per month. The volume of claims continued to fluctuate, with an overall decreasing trend, 
till late 2011. A significant increase was observed during 2012, with the volume of claims 
more than doubling the volume prior to 2011. This increased volume was sustained for 
the rest of the study frame (Figure 5.2). 
Substantive increases in the volume of claims occurred in Quebec during 2004, which 
stabilized in from 2005 to 2011. During 2012, an increase similar to what was observed 
in Ontario was also seen in Quebec, although the magnitude of increase was smaller. 
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Among the remaining study provinces, notable increases were observed in Manitoba 
during 2008. Increases were also observed in Alberta and Nova Scotia during 2011 and in 
New Brunswick and Newfoundland during 2012 (Figure 5.2). 
Considerable changes were also observed among privately insured claims (Figure 5.3), 
and trends mostly followed what was observed in the publicly insured volume of claims. 
In Ontario, the first substantive deviation was the increase observed in 2001. However, 
the increase was again mitigated by a decrease during 2002. The volume of claims 
increased again in 2003 before decreasing till 2006, much like in public claims. 
Substantive increases were again observed in 2006, stabilizing from 2007 to 2009. A 
minor decrease was seen from 2009 to 2011, with significant increases in volume during 
2012 which was maintained for the remainder of the study frame (Figure 5.3). 
Similar trends in the volume of generic claims were also observed in Quebec. Substantial 
increases were observed in 2001 – 2002, with volumes dropping over the remainder of 
2002. Increases in the volume of claims were again observed during 2004, which the 
increased volume of claims sustained till 2011. During 2012, a large increase was seen, 
much like what was detected in Ontario (Figure 5.3).  
Among the rest of the provinces, increases were observed in New Brunswick during 
2001, and again during 2005. The volume of claims then stabilized till 2011 before 
increasing during 2012. Alberta, Nova Scotia, and Newfoundland all saw increases in the 
volume of claims during 2011, which stabilized till the end of the study timeframe. 
Similarly, Manitoba saw increases during 2012, which were sustained till 2013 (Figure 
5.3).
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Figure 5.2 Monthly volume of generic antiglaucoma medication claims for publicly insured prescriptions throughout January 2001 – January 
2013. 
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Figure 5.3 Monthly volume of privately insured antiglaucoma medication dispensed as generic equivalents throughout January 2001 – January 
2013.
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5.3.2 Generic Percentage Dispensed 
Among publicly insured claims (Figure 5.4), the generic percentage dispensed between 
Ontario and Alberta closely approximates one another, with the percentage dispensed 
higher in Ontario. In both provinces, there was an increase in the generic percentage 
dispensed during 2001, with a substantive decrease during 2002. An increase was 
observed on both provinces again in 2003, following by a decrease in the same year till 
2006 for Ontario and 2010 for Alberta. The generic percentage dispensed increased in 
Ontario in 2006 and experienced a slight decrease till 2011, where it significantly 
increased, more than doubling 2011 percentages. The percentage dispensed then 
decreased approximately 8% in 2012, and stabilized for the remainder of the study time 
frame. In Alberta, the decrease from 2003 continued till 2010, where it increased before 
reaching a plateau in the first half of 2011. Increases were again seen in the latter half of 
2011, peaking during early 2012. Like in Ontario, the generic percentage dispensed then 
fell approximately 8% during 2012, prior to stabilizing till 2013 (Figure 5.4). 
The publicly insured generic percentage dispensed in Quebec increased during 2004 
before slowly decreasing during 2005 till 2011. The percentage then increase by 
approximately 6% between 2012 and 2013, surpassing the 2004 peak (Figure 5.4). 
Among the remaining provinces, Manitoba’s generic percentage dispensed decrease from 
2003 to 2008, before increasing during the second half of 2008. The percentage then 
stabilized from 2009 to 2010 (end of data availability). Within the Atlantic provinces, 
increases were observed in Newfoundland during 2008, which stabilized from 2009 to 
2010, before increasing significantly in 2011 and again in 2012. New Brunswick 
displayed similar patterns, with increases in the generic percentage dispensed during 
2010, which stabilized throughout 2011, before increasing again in late 2011. Lastly, 
trends in Nova Scotia mirrored those of New Brunswick, with increases in 2010 and in 
late 2011 (Figure 5.4). 
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Results from the private insured claims present a similar picture to that of the publicly 
insured claims. All of the study provinces saw an increase in the generic percentage 
dispensed during 2001, which stabilized during the first half of 2002. During the latter 
months of 2002, the generic percentage decreased before rebounding in most provinces 
during 2003 (with the exception of Quebec which did not rebound). The generic 
percentages then steadily decreased in all study provinces from 2003 onwards (Figure 
5.5). 
The similar trends between provinces diverged after the increase in 2003. In Ontario, the 
decreasing trend continued until 2006, where a significant increase of approximately 5% 
in the generic percentage dispensed was observed. This increase then stabilized till 2010, 
at which point a slight decrease was observed. The decrease ended during 2011, with a 
doubling of the percentage observed in the first half of 2012. The percentage fell a couple 
percentage points in 2012 before stabilizing till 2013 (Figure 5.5). After the increase in 
2003, the percentage dispensed in Alberta slightly decreased over the 8 years, 
culminating in a decrease of approximately 10%. The percentage then experienced a 
significant increase of roughly 20% between 2011 and 2012, before stabilizing at 25% till 
2013 (Figure 5.5). Within Manitoba claims, the percentage dispensed decreased from 
2003 until 2008, at which point an approximately 13% increase was observed during the 
latter half of 2008. This increase was followed by a slight decrease (approximately 5%) 
over the next three years, and a substantial increase in 2012 (Figure 5.5). 
Interestingly, the generic percentage dispensed among both privately and publicly insured 
claims remained the lowest in Quebec over the majority of the study time frame. The 
decrease in 2003 continued till 2004 in Quebec, whereupon the percentage increased 3% 
during the latter half of 2004. The rate then decreased slightly over 7 years, before 
increasing once again during 2012 (Figure 5.5). 
Among the Atlantic provinces, the generic percentage dispensed in New Brunswick 
increased during 2005, nearly doubling the percentage dispensed prior to 2005. The 
percentage then fell slightly over the next 5 years, but increased approximately 10% 
during the latter half of 2010. A slight decrease of approximately 5% followed during 
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2011, at the end of which a substantive increase of nearly 20% was observed. The 
percentage then decrease before stabilizing around 40% till 2013. In Nova Scotia, the 
decrease from 2003 continued till 2006, at which point the percentage increased 
approximately 10%. This rate then stabilized until 2009, whereupon the percentage had a 
slight increasing trend till 2011. Further increases occurred in Nova Scotia during 2012 
(approximately 20%), however, the rate fell slightly (approximately 5%) during 2012 
before stabilizing in 2013 (Figure 5.5). The decrease in generic percentage dispensed 
from 2003 continued in Newfoundland until 2008, upon which an increase of 
approximately 8% occurred. The rate then stabilized between 2009 and 2010, before 
experiencing an increase for the first half of 2011. The percentage then decreased 
approximately 3% in the latter half of 2011. The percentage dispensed nearly 25% in 
2012 and stabilized as the province with the highest generic percentage dispensed (Figure 
5.5).
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Figure 5.4 Monthly percentage of publicly insured antiglaucoma medication dispensed as generic equivalents throughout January 2001 – 
January 2013. 
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Figure 5.5 Monthly percentage of privately insured antiglaucoma medication dispensed as generic equivalents throughout January 2001 – 
January 2013.
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5.3.3 Generic Dispensing Rate 
The monthly generic dispensing rate of antiglaucoma medication across the study 
provinces are presented in figures 5.6 and 5.7 for publicly and privately insured claims, 
respectively. Among the publicly insured claims (Figure 5.6), a similar trend was 
observed between Ontario and Alberta. Both provinces saw a small spike in the 
dispensing rate during 2001 to 2002, followed by a decrease during the remainder of 
2002. An increase in both provinces occurred during 2003, which was immediately 
followed by a steady decrease starting in the latter half of 2003. This decrease continued 
in Ontario until 2006, where the rate increased slightly over the latter half of 2006. From 
this point, the generic dispensing rate began a small decline between 2007 and 2011, 
before significantly increasing during 2012 (Figure 5.6). In Alberta, the decrease in the 
generic dispensing rate which began in 2003 continued till 2010. The rate began a 
fluctuating increase between 2011 and 2013, culminating at rates nearly triple that of 
2003 values. Interestingly, the dispensing rate for generic antiglaucoma medication was 
the lowest in Alberta across the study time frame among both privately and publicly 
insured claims (Figure 5.6). 
Significant annual trends were observed in Manitoban dispensing rates, with a large surge 
in the rate during the first February of each year. In terms of trends, there was an overall 
decreasing trend in the generic dispensing rate between 2004 and 2008, with rates 
increasing during 2009 and 2010 (Figure 5.6). 
In Quebec, the rate increased during 2004, before stabilized between 2005 through 2011, 
upon which a significant and sustained increase occurred during 2012-2013 (Figure 5.6). 
Among the Atlantic provinces, New Brunswick was relatively stable from 2009 to 2010. 
However, significant increases were observed during 2011 to 2013, which resulted in 
more than a doubling of the generic dispensing rate. Similarly in Nova Scotia, the generic 
dispensing rate was stable from 2007 to 2010, before rapidly increasing during 2011 to 
2013. This increase culminated in a near tripling in the generic dispensing rate, compared 
to 2010 values. Significant bi-annual trends were also observed. The dispensing rate in 
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New Brunswick was stable between 2007 and 2008, before increasing slightly during the 
latter half of 2008. This was followed by another period of stability between 2009 and 
2010. Like in the other Atlantic provinces, the generic dispensing rate in Newfoundland 
increase substantively between 2011 and 2013, which led to a quadrupling of 2008 rates 
(Figure 5.6). 
The privately insured generic dispensing rate (Figure 5.7) mirrored many of the trends 
seen in the publicly insured rates, albeit with a much lower intensity. Much like in the 
other outcome measures, there was a spike in the generic dispensing rates in 2001 and 
parts of 2002 following by a decrease in the remainder 2002 across all study provinces. 
The spikes observed in Ontario during 2003, 2006, and 2012, closely resembles what is 
observed in the publicly funded claims (Figure 5.7). Alberta’s relatively low rates made it 
difficult to distinguish trends in the dispensing rate. However, a decreasing trend between 
2004 and 2010 was noted before a significant increase in the rate was observed during 
2011 to 2013 (Figure 5.7).  
A small spike in generic dispensing rate was seen in Manitoba during 2002, and again in 
2003. Past 2003, the dispensing rate had a slight decreasing trend till 2008. In the second 
half of 2008, the generic dispensing rate substantively increased, nearly doubling the rate 
observed earlier in the year. The increased rate was sustained till 2012, upon which the 
rate significantly increased again to double 2011 rates (Figure 5.7). 
The rate in Quebec also displayed a spike during 2001 and 2002 before falling down to 
pre-spike rates over the remainder of 2002. The rate then continued on a slightly 
increasing trend between 2003 and 2011. During 2012, the generic dispensing rate 
increased substantively, doubling 2011 rates (Figure 5.7). 
Interestingly, the highest generic dispensing rates were observed among the Atlantic 
provinces. The rate in all three Atlantic provinces spiked during 2001 and 2002. In New 
Brunswick, the rate spiked again over the latter half of 2002 before slowly decreasing 
over 2003 to 2005. Another spike over the second half of 2005 saw the New Brunswick 
rate double early 2005 values. This increase was sustained over 2006 to 2010, at which 
point the rate increased again from 2010 to 2013. In Newfoundland, the rate increased in 
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2003, before slowly decreasing from 2003 to 2007. The rate spiked again in 2008, 
doubling 2007 values, and again in 2011, to over 7 times that of 2007 values. These 
increases were sustained till 2013. Rates in Nova Scotia were the lowest among the three 
Atlantic provinces, but the trends observed in New Brunswick were also observed in 
Nova Scotia. The generic dispensing rate increased slightly in the latter half of 2003, 
prior to a slow decrease from 2003 to 2005. The rate increased again in 2006 to 
approximately 1.5 times of 2005 values and was sustained from 2006 to 2010. A 
significant increase was then observed in 2011-2013, with the rate ending at 
approximately 2.5 times that of 2010 values (Figure 5.7).
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Figure 5.6 Monthly rate of privately insured antiglaucoma medication dispensed as generic equivalents per 100,000 residents throughout 
January 2001 – January 2013. 
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Figure 5.7 Monthly rate of privately insured antiglaucoma medication dispensed as generic equivalents per 100,000 residents throughout 
January 2001 – January 2013.
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5.3.4 Total Cost of Antiglaucoma Medication Claims 
The monthly cost of all antiglaucoma medication claims across the study provinces are 
presented in figures 5.8 and 5.9 for publicly and privately insured claims, respectively. 
The monthly cost of both public and privately insured claims increased steadily across all 
study provinces between January 2001 and January 2012. Pronounced annual fluctuations 
were observed across all provinces throughout the study time frame. 
One point of interest is the considerable decrease in total cost of antiglaucoma medication 
claims in Ontario during late 2011 and during 2012. This decrease was observed in both 
publicly and privately insured claims, and is in contrast to the other study provinces, 
where the total cost of antiglaucoma medications remained steady or slightly increased.
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Figure 5.8 Monthly cost of all publicly insured claims for antiglaucoma medication dispensed throughout January 2001 – January 2013. 
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Figure 5.9 Monthly cost of all privately insured claims for antiglaucoma medication dispensed throughout January 2001 – January 2013.
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5.3.5 Summary of Descriptive Results 
Across all three outcome measures, utilization of generic antiglaucoma medications 
fluctuated annually during the study time frame but an overall increase from 2001 to 
2013 was observed. Utilization within the public drug plans was significantly higher than 
utilization within the private drug plans, with the former being twice to ten times higher, 
depending on the province. Significant increases across all outcome measures were 
observed across all provinces during the latter months of 2011 and during 2012. This 
increase was observed in both private and public drug plans, where data was available. 
5.4 Time Series Analysis Results 
Interrupted time series analysis using an ARIMA model was used to determine the level 
of association between the 2010 Ontario Drug System Reform and the various outcome 
measures. Results from these analyses suggested a lack of association between the 2010 
Ontario Drug System Reform and the outcome measures. Furthermore, these analyses 
indicated that the use of price-ceiling policies may not be effective in increasing the 
utilization of cheaper generic antiglaucoma medication. Moreover, the lack of statistically 
significant associations between the drug reform and total drug cost in glaucoma 
treatment suggested that this reform is ineffective in decreasing drug expenditures. 
The Time Series Forecasting System tool within SAS/ETS 9.3 was used to assess the 
congruency of the data to the requirements of the ARIMA modelling technique and to 
determine the best fitting orders of autoregression, integration, and moving average for 
the model. The Augmented Dickey-Fuller test was used to determine the order of 
differencing needed to ensure the stationary requirements of ARIMA modelling are met. 
The Ljung-Box χ2 statistic was calculated for the stationary data to ensure that 
autocorrelation exists between the lags. The ideal model was determined by comparisons 
of goodness-of-fit measures which include the mean square error, adjusted R-square, and 
Schwarz Bayesian Information Criterion. These selection criteria were selected as they 
include the appropriate penalty for models with large numbers of parameters.199 
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To maintain comparable groups between the pre-reform and post-reform periods, 
medications that changed generic status were excluded from the time series analysis. 
Hence, the latanoprost was removed as the first generic equivalent was introduced to the 
Canadian market after the drug reform came into effect (Notice of Compliance for Apo-
latanoprost was issued on August 19, 2011, it was added to the Ontario Drug Benefit 
Formulary on December 15, 2011). 
5.4.1 Volume of Generic Claims 
The model ARIMA (1,1,2)(1,0,0)12 was fitted to the volume of the publicly insured 
generic claims from January 2001 to January 2013. Tests with the three intervention 
functions did not result in differing results, and thus the July 2010 Drug System Reform 
was modelled as the intervention using a ramp function. The statistics of fit using the 
three functions are presented in Table 5.1. Results from the ARIMA procedure indicated 
that the 2010 reform was not statistically associated with a change in the volume of 
publicly funded claims, after taking into account previous trends in generic medication 
use (p = 0.7234). Coefficient estimates from the ARIMA procedure with a ramp 
intervention function are highlighted in Table 5.2. 
Table 5.1 Statistics of Fit of the most appropriate model for each intervention function of the volume 
of generic medication for publicly insured patients. 
Value Statistic of Fit 
Ramp ARIMA 
(1,1,2)(1,0,0)12 
Step 
(1,1,2)(1,0,0)12 
Point 
(1,1,2)(1,0,0)12 
Number of Nonmissing 
Observations 
144 144 144 
Number of Observations 145 145 145 
Number of Missing 
Actuals 
0 0 0 
Number of Missing 
Predicted Values 
1 1 1 
Number of Model 
Parameters 
5 5 5 
Root Mean Square Error 1546.9 1544.4 1544.0 
Adjusted R-Square 0.596 0.597 0.597 
Schwarz Baynesian 2139.9 2139.5 2139.4 
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Information Criterion 
Table 5.2 Coefficient estimates from the ARIMA with a ramp intervention function for the volume of 
generic medication for publicly insured patients. 
Model Parameter  Estimate Standard Error T P-value 
Moving Average, Lag 1 -0.53163 0.1884 -2.8222 0.0055 
Moving Average, Lag 2 0.26479 0.0900 2.9423 0.0038 
Autoregressive, Lag 1 -0.61158 0.1850 -3.3055 0.0012 
Seasonal Autoregressive, Lag 12 0.36762 0.0873 4.2102 <0.0001 
Ramp: July 2010 100.21207 282.5263 0.3547 0.7234 
The monthly volume of privately insured generic claims in Ontario from January 2001 to 
January 2013 was fitted with the model ARIMA (1,1,0)(1,1,0)12. A ramp function was 
utilized to model the 2010 drug reform as there was no difference in the result of ARIMA 
modelling detected using any of the three intervention functions. The statistics of fit using 
the three functions are presented in Table 5.3. Results from the ARIMA procedure 
indicate that the 2010 reform was not statistically associated with a change in the volume 
of privately insured claims, after taking into account previous trends in generic 
medication use (p = 0.7870). Coefficient estimates from the ARIMA procedure with a 
ramp intervention function are highlighted in Table 5.4. 
Table 5.3 Statistics of Fit of the most appropriate model for each intervention function of the volume 
of generic medication for privately insured patients. 
Value Statistic of Fit 
Ramp ARIMA 
(1,1,0)(1,1,0)12 
Step 
(1,1,0)(1,0,0)12 
Point 
(1,1,0)(1,0,0)12 
Number of Nonmissing 
Observations 
132 144 144 
Number of Observations 145 145 145 
Number of Missing 
Actuals 
0 0 0 
Number of Missing 
Predicted Values 
13 1 1 
Number of Model 
Parameters 
3 3 3 
Root Mean Square Error 194.00813 180.03592 180.00199 
Adjusted R-Square 0.627 0.724 0.724 
Schwarz Baynesian 1405.4 1510.5 1510.5 
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Information Criterion 
Table 5.4 Coefficient estimates from the ARIMA with a ramp intervention function for the volume of 
generic medication for privately insured patients. 
Model Parameter  Estimate Standard Error T P-value 
Autoregressive, Lag 1 -0.13181 0.0885 -1.4897 0.1388 
Seasonal Autoregressive, Lag 12 -0.52146 0.0811 -6.4261 <0.0001 
Ramp: July 2010 11.51598 42.5260 0.2708 0.7870 
5.4.2 Generic Percentage Dispensed 
The impact of the 2010 Ontario Drug System Reform on the publicly insured generic 
percentage dispensed was assessed using an ARIMA (1,0,3) model with the use of a ramp 
function. Modelling with a ramp function suggested a statistically significant association 
between the 2010 Drug Reform and a decrease in the generic percentage dispensed (p = 
0.0437). However, this statistical significance was not observed when a step or point 
function was utilized to model the intervention. Table 5.5 presents statistics of fit from 
the best fitting models within each of the three functions. Table 5.6 lists the coefficient 
estimates from the ARIMA procedure with a ramp function. 
Table 5.5 Statistics of Fit of the most appropriate model for each intervention function of the generic 
percentage dispensed as a generic for publicly insured patients. 
Value Statistic of Fit 
Ramp ARIMA 
(1,0,3) 
Step ARIMA 
(1,0,3) 
Point ARIMA 
(1,0,3) 
Number of Nonmissing 
Observations 
144 144 144 
Number of Observations 145 145 145 
Number of Missing Actuals 0 0 0 
Number of Missing Predicted 
Values 
1 1 1 
Number of Model Parameters 6 6 6 
Root Mean Square Error 0.01661 0.01676 0.01678 
Adjusted R-Square 0.875 0.873 0.873 
Schwarz Baynesian 
Information Criterion 
-1150.3 -1147.7 -1147.5 
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Table 5.6 Coefficient estimates from the ARIMA with a ramp intervention function for the generic 
percentage dispensed among publicly insured patients. 
Model Parameter  Estimate Standard Error T P-value 
Intercept 0.32745 0.0121 27.1190 <0.0001 
Moving Average, Lag 1 -0.40367 0.1027 -3.9318 0.0001 
Moving Average, Lag 2 0.01543 0.1187 0.1300 0.8967 
Moving Average, Lag 3 -0.26685 0.0928 -2.8766 0.0047 
Autoregressive, Lag 1 0.79715 0.0740 10.7783 <0.0001 
Ramp: July 2010 -0.00260 0.0013 -2.0357 0.0437 
An ARIMA (2,1,1) model with the intervention modelled using a ramp function was 
fitted to the generic percentage dispensed for the privately insured claims. Intervention 
modelling using a point, step, or ramp function did not affect the non-significant of the 
impact of the 2010 Drug System Reform on the percentage dispensed in either the 
publicly or privately insured patient population. Statistics of fit for the most appropriate 
model for each of the intervention functions are presented in Table 5.7. The 2010 drug 
reform was not associated with a statistically significant change in the generic percentage 
dispensed (p=0.7377). Table 5.8 presents results from the ARIMA modelling with a ramp 
intervention function. 
Table 5.7 Statistics of Fit of the most appropriate model for each intervention function of the generic 
percentage dispensed among privately insured claims. 
Value Statistic of Fit 
Ramp ARIMA 
(2,1,1) 
Step 
ARIMA(2,1,1) 
Point 
ARIMA(2,1,1) 
Number of Nonmissing 
Observations 
144 144 144 
Number of Observations 145 145 145 
Number of Missing Actuals 0 0 0 
Number of Missing Predicted 
Values 
1 1 1 
Number of Model Parameters 4 4 4 
Root Mean Square Error 0.01632 0.01631 0.01630 
Adjusted R-Square 0.835 0.835 0.835 
Schwarz Baynesian 
Information Criterion 
-1165.3 -1165.6 -1165.8 
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Table 5.8 Coefficient estimates from the ARIMA with a ramp intervention function for the generic 
percentage dispensed among privately insured claims. 
Model Parameter  Estimate Standard Error T P-value 
Moving Average, Lag 1 -0.94822 0.0401 -23.6464 <0.0001 
Autoregressive, Lag 1 -0.86358 0.0890 -9.6977 <0.0001 
Autoregressive, Lag 2 -0.13675 0.0871 -1.5691 0.1189 
Ramp: July 2010 -0.0009817 0.0029 -0.33556 0.7377 
5.4.3 Generic Dispensing Rate 
The generic dispensing rate of publicly insured antiglaucoma medication per 100,000 
Ontario residents from January 2001 to January 2013 was fitted using various ARIMA 
models, depending on the type of intervention function used. The 2010 Ontario Drug 
System Reform introduced as an intervention using a ramp function as no differences was 
observed in the significance of the intervention using either a ramp, step or point 
function. The most appropriate model, along with statistics of fit, for each of the 
intervention functions are presented in Table 5.9. No significant change in the publicly 
insured generic dispensing rate attributable to the drug reform was observed (p=0.5911). 
Coefficient estimates from the ARIMA modelling with a ramp intervention function are 
listed in Table 5.10. 
Table 5.9 Statistics of Fit of the most appropriate model for each intervention function of the generic 
dispensing rate per 100,000 residents for publicly insured patients. 
Value Statistic of Fit 
Ramp ARIMA 
(1,1,2)(0,1,1)12 
Step 
ARIMA(1,1,2)(0,1,1)12 
Point 
ARIMA(1,1,2) 
(1,0,1)12 
Number of 
Nonmissing 
Observations 
132 132 144 
Number of 
Observations 
145 145 145 
Number of Missing 
Actuals 
0 0 0 
Number of Missing 
Predicted Values 
13 13 1 
Number of Model 5 5 6 
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Parameters 
Root Mean Square 
Error 
11.59694 11.60319 11.36156 
Adjusted R-Square 0.661 0.660 0.662 
Schwarz Baynesian 
Information 
Criterion 
671.4094 671.55195 729.72680 
 
 
Table 5.10 Coefficient estimates from the ARIMA with a ramp intervention function for the generic 
dispensing rate per 100,000 residents for publicly insured claims. 
Model Parameter  Estimate Standard Error T P-value 
Moving Average, Lag 1 -0.72779 0.1418 -5.1326 <0.0001 
Moving Average, Lag 2 0.19377 0.1005 1.9288 0.0560 
Seasonal Moving Average, Lag 12 0.86454 0.1405 6.1547 <0.0001 
Autoregressive, Lag 1 -0.68407 0.1215 -5.6286 <0.0001 
Ramp: July 2010 1.04822 1.9459 0.5387 0.5911 
An ARIMA (1,1,0)(1,1,0)12 model was fitted to the generic dispensing rate of privately 
insured generic medication per 100,000 Ontario residents from January 2001 to January 
2013. Again, a ramp function was utilized to introduce the intervention as no differences 
were observed between the three functions in the significance of the impact of the drug 
reform. The statistics of fit for the most appropriate model for each intervention function 
is presented in Table 5.11. ARIMA estimates suggested no significant change in the 
generic dispensing rate as a result of the drug reform (p=0.7956). Estimates from the 
ARIMA model with a  ramp intervention function are presented in Table 5.12. 
Table 5.11 Statistics of Fit of the most appropriate model for each intervention function of the 
generic dispensing rate per 100,000 residents for privately insured patients. 
Value Statistic of Fit 
Ramp ARIMA 
(1,1,0)(1,1,0)12 
Step 
ARIMA(1,1,0)(1,1,0)12 
Point 
ARIMA(2,1,0) 
(1,1,0)12 
Number of 
Nonmissing 
132 132 132 
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Observations 
Number of 
Observations 
145 145 145 
Number of Missing 
Actuals 
0 0 0 
Number of Missing 
Predicted Values 
13 13 13 
Number of Model 
Parameters 
3 3 4 
Root Mean Square 
Error 
1.54674 1.54697 1.54535 
Adjusted R-Square 0.556 0.556 0.553 
Schwarz Baynesian 
Information 
Criterion 
129.79220 129.83149 134.43806 
Table 5.12 Coefficient estimates from the ARIMA with a ramp intervention function for the 
dispensing rate of generic medication per 100,000 residents for privately insured claims. 
Model Parameter  Estimate Standard Error T P-value 
Moving Average, Lag 1 -0.12900 0.0887 -1.4550 0.1481 
Seasonal Moving Average, Lag 12 -0.52283 0.0797 -6.5570 <0.0001 
Ramp: July 2010 0.08783 0.3384 0.2595 0.7956 
5.4.4 Total Cost of Antiglaucoma Medication Claims 
The monthly total cost of publicly insured antiglaucoma medication over the study time 
frame was fitted using various ARIMA models, depending on the type of intervention 
function used. Introducing the 2010 Ontario Drug System Reform using a ramp function 
led to a statistically significant association between the reform and an increase in monthly 
total cost of publicly insured antiglaucoma claims (p=0.0027), but this significance was 
not observed when using a step or point function. The models, along with statistics of fit, 
for each of the intervention functions are presented in Table 5.13. Coefficient estimates 
from the ARIMA modelling with a ramp intervention function are listed in Table 5.14. 
Table 5.13 Statistics of Fit of the ARIMA model for each intervention function of the total cost of 
antiglaucoma medication claims for publicly insured patients. 
Value Statistic of Fit 
Ramp ARIMA Step Point ARIMA 
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(12,1,2) ARIMA(12,1,3) (12,1,1) 
Number of Nonmissing 
Observations 
144 144 144 
Number of Observations 145 145 145 
Number of Missing Actuals 0 0 0 
Number of Missing Predicted 
Values 
1 1 1 
Number of Model Parameters 15 16 14 
Root Mean Square Error 90824.0 92687.3 95013.8 
Adjusted R-Square 0.982 0.981 0.981 
Schwarz Baynesian 
Information Criterion 
3362.6 3373.4 3370.6 
Table 5.14 Coefficient estimates from the ARIMA with a ramp intervention function for the total 
cost of antiglaucoma medication claims for publicly insured claims. 
Model Parameter  Estimate Standard Error T P-value 
Moving Average, Lag 1 0.71807 0.1226 5.8559 <0.0001 
Moving Average, Lag 2 -0.49559 0.1190 -4.1645 <0.0001 
Autoregressive, Lag 1 0.13429 0.1022 1.3136 0.1913 
Autoregressive, Lag 2 -0.11117 0.0991 -1.1222 0.2639 
Autoregressive, Lag 3 0.01549 0.0775 0.1999 0.8419 
Autoregressive, Lag 4 -0.32948 0.0752 -4.3813 <0.0001 
Autoregressive, Lag 5 0.22826 0.0855 2.6706 0.0085 
Autoregressive, Lag 6 -0.11841 0.0844 -1.4030 0.1630 
Autoregressive, Lag 7 -0.01287 0.0773 -0.1665 0.8680 
Autoregressive, Lag 8 -0.22790 0.0767 -2.9707 0.0035 
Autoregressive, Lag 9 0.09908 0.0856 1.1576 0.2492 
Autoregressive, Lag 10 -0.20367 0.0817 -2.4933 0.0139 
Autoregressive, Lag 11 0.07954 0.0802 0.9921 0.3230 
Autoregressive, Lag 12 0.56752 0.0851 6.6717 <0.0001 
Ramp: July 2010 33867 12690 3.0629 0.0027 
One statistically significant positive association between the 2010 Ontario Drug System 
Reform and the total cost of privately insured medication was observed when the 
intervention was introduced using a point function (p=0.0447). However, this 
significance did not carry over when a ramp or step function was used. The statistics of 
fit for the models for each intervention function is presented in Table 5.15. Estimates 
from the ARIMA models with a ramp intervention function are presented in Table 5.16. 
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Table 5.15 Statistics of Fit of the ARIMA model for each intervention function of the total cost of 
antiglaucoma medication claims for privately insured patients. 
Value Statistic of Fit 
Ramp ARIMA 
(2,1,2)(1,1,0) 
Step ARIMA 
(2,1,2)(1,1,0) 
Point ARIMA 
(3,1,0)(1,1,0) 
Number of Nonmissing 
Observations 
132 132 132 
Number of Observations 145 145 145 
Number of Missing 
Actuals 
0 0 0 
Number of Missing 
Predicted Values 
13 13 13 
Number of Model 
Parameters 
6 6 5 
Root Mean Square Error 11855.6 11769.7 11989.3 
Adjusted R-Square 0.989 0.990 0.989 
Schwarz Baynesian 
Information Criterion 
2505.8 2503.8 2503.8 
Table 5.16 Coefficient estimates from the ARIMA models for the total cost of antiglaucoma 
medication claims for privately insured patients. 
Model Parameter  Estimate Standard Error T P-value 
Moving Average, Lag 1 -0.64223 0.1093 -5.8769 <0.0001 
Moving Average, Lag 2 -0.55769 0.1026 -5.4335 <0.0001 
Autoregressive, Lag 1 -1.12497 0.0722 -15.5914 <0.0001 
Autoregressive, Lag 2 -0.87359 0.0599 -14.5782 <0.0001 
Seasonal Autoregressive, Lag 12 -0.42391 0.0947 -4.4786 <0.0001 
Ramp: July 2010 2757 2330 1.1836 0.2388 
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Chapter 6  
6 Discussion 
6.1 Descriptive Analysis 
This population-based study of the utilization of generic antiglaucoma medications found 
that the use of these drugs increased in the time span between January 2001 and January 
2013. This increase in the level of utilization may be consequences of the introduction of 
the first generic equivalent of brand name antiglaucoma compounds or due to the 
influences of policies that limited the price of generics, thereby making these medications 
cheaper to use. Results from this study indicated that the utilization rate of privately 
insured generic antiglaucoma medications ranged from 10.54% to 18.76% between 
provinces in January 2001, increasing to 13.91% to 48.14% in January 2013. While such  
increases in the use of cheaper, generic equivalents are beneficial in terms of cost-savings 
for both private and public drug insurance plans, this finding indicated that level of 
generic drug utilization in privately insured glaucoma patients during 2012 is lower in 
comparison to the overall generic prescription drug utilization rate of 63.2%, as estimated 
by the Canadian Generic Pharmaceutical Association.200 Hence, there may be additional 
cost savings which can be realized if the utilization of generic medication in glaucoma 
treatment continues to increase.  
6.1.1 Volume of Generic Claims 
The decreasing trend in the volume of both privately and publicly insured generic 
antiglaucoma medication claims across study provinces post 2002 may be reflective of 
the increased usage of prostaglandins in glaucoma therapy. Patients who were previously 
prescribed a generic antiglaucoma medication, such as timolol maleate, may have 
switched over to brand name prostaglandins and other combination medications, due to 
its greater effectiveness in controlling intraocular pressure and lower rates of systemic 
side effects. As a result, these patients now utilized a brand name compound and would 
not contribute to the volume of generic claims, leading to the decrease in utilization 
observed. Such a conclusion agrees with previous research which demonstrated that upon 
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introduction, prostaglandins, namely latanoprost, quickly became the most popular 
therapeutic agent for glaucoma and displaced the market shares of older therapeutic 
agents.119,123,124 
The approval of Ratio-Brimonidine, which is a generic equivalent of Alphagan (Notice of 
Compliance issued on June 17th, 2002), may have contributed to the observed increase in 
the volume of generic claims in Ontario during 2003.201 The introduction of the first 
generic equivalent may have caused a rapid migration of patients who use to receive 
Alphagan towards the cheaper, generic equivalent. As a result, a large increase in the 
volume of generic claims was observed once the generic was made available for patients.  
In contrast to the decreasing trend observed in the other provinces, there was an increase 
in the volume of generic medications dispensed in Ontario during Quarter 3, 2006. This 
increase may be associated with the introduction of the 2006 Transparent Drug System 
for Patients Act, which lowered the cost of generic medications and widened the 
definition of interchangeability under the DIDFA.150 The decreased cost of generic 
medications may have made it more affordable for patients and may have encouraged 
substitution from brand name medications to its generic equivalents, thereby explaining 
the increased volume of claims observed. Similar increases in the utilization of generic 
equivalents were observed in Austria among the usage of generic PPIs and statin 
medication after various reforms and initiatives (including reference pricing reform 
similar to the 2006 reform) were introduced.160 Furthermore, this reform may have 
caused more prescriptions being substituted with a generic equivalent as a result of the 
increased availability of generic choices, thereby leading to the increase in utilization 
observed. The fact that the increase was observed only in the province of Ontario, where 
the policy change was enacted, adds credibility to this explanation. 
Interestingly, the substantive increase in the volume of generic claims observed across all 
provinces beginning in Quarter 3, 2011 coincides with the introduction of generic 
latanoprost to the Canadian market (Notice of Compliance for Apo-latanoprost was 
issued on August 19, 2011). This observation may indicate that the introduction of the 
first generic equivalent for a therapeutic class has a significant impact on the utilization 
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of generic drugs. This association between the approval of the first generic equivalent and 
the increase in generic utilization could possibly be mediated by mandatory generic 
substitutions rules enacted by many drug plans.130,202–204 These laws mandate that a 
prescription must be dispensed using a generic equivalent, where available. Thus, an 
increase in generic utilization is understandable as patients will be dispensed the newly 
approved generic equivalents in favour of Xalatan (the brand name latanoprost product). 
6.1.2 Generic Percentage Dispensed 
Much like in the volume of claims, the decrease in generic percentage dispensed 
observed during 2003 across all provinces may be a consequence of the introduction of 
Travatan to the Canadian market. This brand name prostaglandin was rapidly prescribed 
in glaucoma treatment. As a result, patients who were using older generic antiglaucoma 
medication may have been switched to this new prostaglandin, resulting in the observed 
decrease in generic percentage dispensed. 
The increase in the generic percentage dispensed across the provinces (except Quebec) in 
Quarter 1, 2003 may be due to the introduction of generic brimonidine to the Canadian 
market. This introduction may have lead many patients who received Alphagan to be 
instead dispensed generic brimonidine. As a result, the utilization of generic medication 
increase and the corresponding generic percentage dispensed also increased. A rationale 
for the lack of change in Quebec may be due to its unique reimbursement scheme, which 
provided full cost reimbursement for Alphagan, even after a generic equivalent is 
available. Hence, patients lost the financial incentive to substitute prescriptions for 
Alphagan with its generic equivalent. Additional details regarding this unique 
reimbursement scheme is provided below. 
The increase in the generic percentage dispensed observed in Ontario beginning in 
Quarter 2, 2006 may be a result of the introduction of the 2006 Transparent Drug System 
for Patients Act. The possible ramifications of this reform are presented above, and may 
have led to an increase in the volume of generic claims. This in turn would have led to a 
corresponding decrease in the volume of brand name claims. Hence, this may have 
resulted in the observed increase in the generic percentage dispensed. 
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Increases in generic percentage dispensed observed during Quarter 2, 2008 in Manitoba 
and Newfoundland may be due to changes in their respective drug program policies. 
Effective April 1st, 2008, the Manitoban Pharmacare program raised the deductible rates 
for its beneficiaries. This increase may have provided financial incentives for patients to 
substitute their brand name prescriptions with a generic equivalent in order to lessen the 
impact of the increase in deductible fees. However, this change in the deductible may 
only have a small impact on the change in generic percentage dispensed as it was only a 
5% change in the rate (from between 2.56% and 5.51%, to between 2.69% and 5.79%). 
An alternative rationale for the observed increase is the introduction of Apo-Timop Gel, a 
generic version of Timoptic-XE, to the province of Manitoba during August 2008. 
Hence, patients who previously received Timoptic-XE may have had their prescription 
substituted with Apo-Timop Gel, thereby contributing to the increase in generic 
percentage dispensed. Similarly, Timolol Maleate-EX was introduced to Newfoundland 
during July 2008 which may have contributed to the corresponding increase in generic 
percentage dispensed. The latter explanation is more relevant as the increase was 
observed in both private and public insurance claims, whereas the former explanation 
should only affect publicly insured claims. 
The increases in generic percentage dispensed during Quarter 3, 2010 observed in New 
Brunswick, Nova Scotia, Alberta and Newfoundland may be due to the introduction of 
Apo-Dorzo-Timol, Sandoz-Dorzol-Timop, Sandoz-Dorzolamide, which are generic 
equivalents of Cosopt and Trusopt, respectively. Having these generic equivalents 
available may have led patients to substitute their brand name prescriptions with the 
corresponding generic drug, and thus causing the increase in generic percentage 
dispensed observed. 
Again, like in the volume of claims, the increased generic percentage dispensed observed 
in Quarter 4, 2011 across all provinces are most likely associated with the introduction of 
generic latanoprost during that period. This introduction of the generic equivalent of this 
popular antiglaucoma agent may have patients who were previously using Xalatan, 
Travatan or Lumigan to substitute their prescriptions with the generic latanoprost. This in 
turn may explain the substantive increases in generic percentage dispensed. 
78 
 
 
 
The low dispensing percentage observed in the province of Quebec may be due to its 
unique reimbursement policy. Quebec offers full reimbursement for the price of brand 
name medications listed on its formulary for 15 years, even if generic equivalents are 
introduced within that time frame.205 This is in contrast to the policies in other provinces, 
which often limit the amount reimbursed for brand name medication to the price(s) of the 
generic equivalent(s).130 As a result, patients in Quebec lose the economic incentives to 
switch to a cheaper generic medication, which may explain the low dispensing 
percentages in the province.205 In fact, estimates by Canadian Generic Pharmaceutical 
Association identified Quebec as the provinces with the lowest generic market share in 
2012, and that the differences in generic market share across the provinces was due to the 
heterogeneity between the various drug programs implemented.206 
6.1.3 Generic Dispensing Rate 
Results from the generic dispensing rate outcome measure revealed similar trends to the 
other outcome measures. Introduction of the first generic equivalent for brand name 
compound remain one of the strongest driving forces for changes in the generic 
dispensing rate. However, the generic dispensing rate revealed that the dispensing rate is 
the lowest in Alberta, and highest in the Atlantic provinces. These results will be 
discussed below. 
Compared to the other provinces included in this study, generic dispensing rates were 
lowest in Alberta. There are two possible explanations for this observation. First, the low 
rates of generic antiglaucoma medication dispensed in Alberta compared to the other 
provinces may be due to a lower demand for antiglaucoma medication in general 
(including both brand name and generic medication). This explanation is supported by 
the younger age distribution in Alberta. For example, the percentage of Alberta between 
the ages of 15-64 and 65 and older are 70.1% and 11.1%, respectively, while the 
corresponding national percentages are 68.5% and 14.8% (in 2011).207 Hence, the 
prevalence of glaucoma may be lower in Alberta as glaucoma is typically a disease of the 
elderly. This may lead to a decreased demand for antiglaucoma medication in general, 
and explain the lower rates of generic antiglaucoma medication dispensed. An alternative 
explanation for the low generic dispensing rate in Alberta may be an under-utilization of 
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generic medication compared to the other provinces in the study. However, taking into 
consideration the relatively high generic percentage dispensed in comparison to the other 
provinces, it does not appear that Alberta is under-utilizing generic antiglaucoma 
medication. 
With respect to the increased generic dispensing rate seen in the Atlantic provinces, a 
possible explanation may be the fact that the percentage of people 65 and older are higher 
in these provinces than national average. According to Statistics Canada, the proportion 
of people over the age of 65 in 2011 is 16.5%, 16.6%, and 16.0% in New Brunswick, 
Nova Scotia, and Newfoundland and Labrador, respectively, compared to the national 
estimate of 14.8%.207 Hence, the prevalence of glaucoma may be higher in these 
provinces relative to the other provinces in the study. Thus, there may be greater demand 
for antiglaucoma medication, explaining the observed greater generic dispensing rates 
observed. 
6.1.4 Total Cost of Antiglaucoma Medication Claims 
In terms of the total cost of antiglaucoma medication, the considerable decrease in total 
cost observed in Ontario during Quarter 4, 2011 may be due to the introduction of generic 
latanoprost to the Canadian market. Much like in the other outcome measures, this 
introduction may have caused a shift from the expensive, brand name Xalatan, Travatan 
or Lumigan to the cheaper generic latanoprost, causing the total cost of antiglaucoma 
medication to decrease. Another point which adds credibility to this explanation is that 
the decrease was observed in the other provinces as well, which would indicate that the 
catalyst for change must originate at the national level. Such a change can be spurred by 
the approval of a generic medication for the Canadian market. 
Due to this study being the first to examine the utilization patterns of generic 
antiglaucoma medication in Canada, comparisons to other scholarly works cannot be 
made regarding the results of the study. 
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6.2 Time Series Analysis 
The 2010 Ontario Drug System Reform sought to reduce the public and private drug 
expenditure by lowing maximum reimbursement and enacting price ceiling on the price 
of generic medications, respectively. Within the non-solid dosage forms, the reform 
mandated the cost of generic equivalent to no more than 35% of the reference product. 
Hence, we aimed to determine the impact of this reform on the utilization and total drug 
expenditures on antiglaucoma medication within Ontario. It is proposed that the reform 
should lead to a decrease in both the public and private drug expenditures as the prices of 
generic equivalents are often lower than that of the brand name counterparts; 
furthermore, due to the lower drug costs, the use of generic equivalents may become a 
more attractive opinion and therefore utilization may increase as result. 
The results from the time series analysis of the impact of the 2010 Ontario Drug System 
Reform yielded mixed results. Several statistically significant associations were observed 
between the outcome measures and the drug system reform. Namely, a decrease in the 
publicly insured generic percentage dispensed was associated with the reform while an 
increase in the total cost of both privately and publicly insured claims were associated 
with the reform. The significant results could be understood when examined together. 
The decrease in percentage of generic antiglaucoma medication associated with the 2010 
reform may suggest that brand name medications saw increased utilization in the post-
reform time frame. This decrease in the use of generic medications (and the subsequent 
increase use of brand name medication) may be due to the removal of the professional 
allowanced mandated as part of the reform. The discontinuation of professional 
allowances removes the financial incentives of pharmacies to substitute brand name 
prescriptions with its generic equivalents.205 Consequently, this increase in the use of 
relatively more expensive brand name drug may lead to an increase in total cost of both 
privately and publicly insured medications and thus explain the increase in total drug 
costs associated with the drug system reform. 
However, it is important to note that none of the other outcome measures demonstrated 
statistical significance with the 2010 Ontario Drug System Reform. Moreover, each of 
these significance results was observed in only one of the three methods used to introduce 
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the intervention parameter. This inconsistency in the statistical significance between the 
intervention parameters suggests that the observed significance may be spurious. 
Furthermore, the lack of consensus among the outcome measures provide further 
evidence that the significant associations observed may be invalid. 
The non-significant results from the time series analysis may be reflective of the 
parameter of the study, where only antiglaucoma medications in the non-solid 
formulations were included. Due to the unique reimbursement scheme when price caps 
for non-solid dosages are higher than in solid formulations, the impact of the reform may 
be muted. The higher price caps for generic medication may reduce the financial 
incentives for patients to request their medication be substituted with a generic 
equivalent. As a result, changes in use of generic medication in glaucoma treatment may 
be lower and non-significant compared to studies evaluating the impact of the reforms on 
solid formulation medications. 
Based on the literature review, this is the first study looking at the impact of drug pricing 
reforms on the utilization of generic antiglaucoma medications worldwide. Outside of the 
field of glaucoma, prior research has been conducted on the impact of the 2010 Ontario 
Drug System Reform on drugs costs. However, methodological differences limit the 
comparability of results. For instance, Law et al., in their study into the short-term impact 
of the 2010 reform, determined that the drug reform was responsible for a $181 to $194 
million decrease in generic drug expenditure in the 6 months after the introduction of the 
reform. However, it is important to note that while our study only looked at the impact on 
antiglaucoma medications, their study was examining the impact on all generic 
medication expenditures. Hence, the cost saving they observed may not hold for the 
glaucoma medication market, resulting in the discrepancies between the results. 
Internationally, a study from Austria examined the impact of a plethora of other reforms 
and initiatives to contain drug expenditures, including reference pricing reforms, on the 
utilization of proton pump inhibitors and statins.160 The study determined that these 
reforms and initiatives were correlated with an increased usage of PPIs and statins. 
However, it did not determine specifically the impact of the introduction of reference 
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pricing reforms on the utilization of these drugs.160 The impact of reference pricing in 
Germany were also examined, which identified that the introduction of reference pricing 
in 1993 lead to a 36% increase in the sales of the four largest generic manufacturers and a 
decrease in 16.5% in sales among the top seven research intensive drug manufacturers.161 
This finding suggests that the introduction of price limiting policies, much like the 
Ontario reforms, may consequently increase the utilization of generic equivalents at the 
expense of brand name compounds. Similar observations were seen in the Swedish 
markets, where reference pricing was introduced in 1993.163 When comparing first 6 
months of 1993 with the remainder of 1993, the market share for brand name compounds 
decrease from 65% to 51%, while the market share for generic equivalents increased.162 
This shift in the market shares translated to a savings of about 5% of the total drug 
expenditure.162 
The results of this study do not agree with many of the studies that examine the impact of 
the introduction of reference pricing, which suggest that such policies should increase the 
utilization of generic compounds. However, it is important to note that there are 
significant differences between these studies and the present study. Firstly, the current 
study examined only the impact on antiglaucoma medications, whereas the other studies 
examined the impact of these policies on all medications. Second, differences in the 
methods used to determine the reference price may impact the financial incentives a 
patient faces when making the decision to substitute with a generic equivalent. For 
example, the reference in Germany is determined by taking the average of all the drugs 
within the interchangeable group, whereas in Canada, the reference price is set at an 
arbitrary percentage of the brand name compound.139 These differences may limit the 
appropriateness of comparing the results of these international studies with those of this 
study. 
The effect of both the 2006 and 2010 Ontario Drug System Reform was also evaluated. 
However, much like in the above analysis, no persistent statistically significant result was 
observed in that neither the 2006 or 2010 reforms were statistically significantly 
associated with a change in the outcome measures of this study. Hence, the result of this 
sub-analysis was included in Appendix A. 
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6.3 Study Strengths 
This study has several strengths. Based on the literature review, this study is the first to 
describe the utilization patterns of generic medication in glaucoma treatment in Canada. 
Moreover, it is one of a few studies that have empirically measured the impact of the 
Ontario Drug System Reforms on the utilization of generic medications in Ontario. 
Furthermore, since the population-based analyses included all insured claims for 
antiglaucoma medication within the provinces examined, the study avoided the potential 
for bias such as selection bias which may influence the results observed. 
6.4 Study Limitations 
This study also has several limitations. First, only insured claims for prescription 
antiglaucoma medication dispensed was available. Hence, this study does not consider 
the utilization of generic antiglaucoma medication among patients who are uninsured and 
pay out-of-pocket. However, it is expected that the majority of the prevalent cases of 
glaucoma are among the elderly and are thus insured by a public drug insurance plan. 
Moreover, a 2002 estimate by the Fraser Group indicated that only 2% of Canadians do 
not have access to any form of drug plan coverage, and thus would not be captured within 
the database.208 Estimates from the Canadian Institute for Health Information suggested 
that approximately 16% of total drug expenditures in Canada are financed by out-of-
pocket payments by Canadians.209 However, this estimate included any co-payments that 
households paid as part of their insurance agreements and therefore the number of non-
insured Canadians may be substantively lower. As only a small fraction of Canadians do 
not have any form of drug insurance, the sample utilized and results obtained in this study 
should provide a generalizable view of the utilization of generic antiglaucoma medication 
in Canada. 
Second, the database did not identify patients who were covered by both public and 
private insurance plans during the study time frame. As a result, duplicity of claims may 
result which are not accounted for within the database, as patients who have public 
coverage for a portion of the drug cost may also utilize a private drug plan to pay for the 
remaining cost. This scenario may result in a claim to appear in both the private and 
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public drug claims databases. Hence, the analyses of private drug claims may not reflect 
the true drug utilization patterns of patients who are covered solely by a private drug 
plan. Unfortunately, given the nature of the dataset, it was impossible to determine how 
many of claims were made by patients who are covered by both public and private 
insurance plans. 
Third, this study utilized data that was aggregated at a provincial level, and thus was 
unable to capture the differences in generic medication utilization at the local health 
region level. For this reason, effects of geographical factors, such as urbanicity, on 
generic medication utilization could not be assessed. Such subgroup analyses may reveal 
interesting results as the lack of access to healthcare in rural areas, coupled with concerns 
regarding differences in effectiveness and rates of side effects between brand name 
products and generic equivalents may lead rural clinicians to avoid the use of generic 
medications. The aggregate nature of the data also limited the ability to explore 
differences in utilization among different subgroup of patients, such as severe glaucoma 
patients versus mild glaucoma patients, or younger versus older patients. Furthermore, 
utilization patterns among patients in differing socio-economic classes could not be 
assessed. 
Fourth, this study only evaluated the utilization of non-solid formulation medication for 
glaucoma treatment. As a result, solid formulation medications (ie. tablet form) were 
excluded from the analysis. This segregation was necessary as there is a difference in the 
reimbursement scheme for non-solid formulation versus solid formulation medications. 
Based on the literature review, there are no studies conducted which examined the market 
share of solid formulations within the antiglaucoma medication market. However, from 
the dataset utilized in this study, the average monthly market share of solid formulations 
across the study provinces ranged from 1.6% to 8.1% and 1.2% to 2.9% for private and 
public insured claims, respectively. Hence, the impact of the non-solid formulations on 
the results generated within this study may be negligible. 
Lastly, another limitation of this study was that unmeasured confounders were unaccounted for, 
which may introduce shocks to our data that could not be adjusted for by the modelling 
technique. An example of such confounding elements would be a population change beyond 
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expectation, which could arise due to atypical levels of immigration. Such an element may be an 
above average increase in the proportion of elderly immigrants, which may potentially 
lead to an increase in the number of glaucoma patients and an increase in the utilization 
of glaucoma medication that is unrelated to the policy changes examined. However, 
given that the data was stationary upon differing, the impact of these unmeasured 
confounders is minimal. 
6.5 Study Implications 
The study results demonstrated by the end of 2012, when generic equivalents were 
available for all five antiglaucoma medication classes, only approximately half of all 
medications prescribed were dispensed as a generic equivalent. Hence, potential cost 
savings to drug insurance plans may be realized by encouraging increased utilization of 
generic equivalents. However, such a push may be difficult as there is contention in the 
ophthalmological field regarding the equivalence of generic ophthalmic solutions to the 
brand reference products. Although a generic drug must prove bioequivalence in order to 
obtain approval from Health Canada, such claims for ophthalmic drugs are often derived 
from studies in animal models, and may not be reflective of the drug’s activity in 
humans.210 Moreover, generic manufacturers of aqueous solutions (which include all 
ophthalmic solutions) can request waivers to avoid demonstrating in vivo 
bioequivalence.211 Instead the manufacturers need only provide comparisons of the 
formulation, physicochemical properties, and device attributes between the reference 
product and their generic compound.211 Furthermore, studies have cited differences in the 
excipients (non-active ingredients) and bottle design between the brand name and generic 
products which may impact the equivalency, and ultimately its therapeutic value.212,213 
These concerns may lead a clinician to hesitate in prescribing generic equivalents for his 
or her patients. Patient perceptions towards generic medications may also limit its used in 
practice.214,215 
The findings of this study also suggested that the introduction of a price ceiling on 
generic medication may not translate to an increase in utilization. Hence, efforts to 
increase utilization of generic medication should instead focus on other modifiable 
factors that may influence the choice to use a generic equivalent. For example, public 
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awareness programs regarding the equivalency between generic medication and brand 
name drugs may change patient perceptions towards generics and increase their 
confidence in the use of these drugs. Furthermore, more stringent testing for ophthalmic 
generic equivalents may convince clinicians to prescribe generic medications for their 
patients. 
6.6 Future Research 
More research is needed to fully understand the impacts of a price limiting policy such as 
the 2010 Ontario Drug System Reform on the utilization of generic medications. 
Adopting the methodologies used in this study, further research can be conducted on the 
other provinces within Canada as most have enacted policies to introduce a price-ceiling 
for generic medications. Collectively, the results of these studies can provide a more 
comprehensive assessment of price-limiting reforms on the utilization patterns of generic 
drugs 
Furthermore, research on the association between different covariates, such as 
geographical location, socioeconomic status and disease severity on generic antiglaucoma 
drug utilization may provide interesting results regarding the utilization pattern. 
Understanding how these covariate influence the use of generic equivalents can guide the 
development of novel programs to increase the use of these drugs and potentially reduce 
the cost of treatment for glaucoma patients. 
6.7 Conclusion 
In this study, the utilization patterns of generic antiglaucoma medications were examined 
through the use of Canadian insured drug claim records. It was demonstrated that there 
was an overall increase in the utilization of generic antiglaucoma medications between 
January 2001 and January 2013 in all of the provinces examined. Furthermore, there was 
insufficient evidence to suggest that the 2010 Ontario Drug System Reform was 
associated with a change in the utilization of generic antiglaucoma medication in Ontario. 
Based on these results, policy makers should target efforts aiming to increase the 
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utilization of generic medication on other factors which influences one’s decisions to 
using generic medication. 
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Appendix A 
Analysis of the Impact of both the 2006 Transparent Drug 
System for Patients Act and the 2010 Ontario Drug System 
Reform 
Further analyses were conducted to determine the impact of the 2006 Transparent Drug 
System for Patients Act and the 2010 Ontario Drug System Reform on the various 
outcome measures. One significant result was observed for the analysis regarding the 
monthly total cost of publicly insured antiglaucoma medication claims. Modelling both 
interventions through the use of a ramp function, both the 2006 and 2010 reform was 
associated with an increase in the monthly total cost, however, only the 2010 intervention 
parameter was statistically significant (p=0.0476). No other significant results were 
obtained from the analysis of the remaining outcome measures. Results from the best 
fitting ARIMA models are presented below. 
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Volume of Generic Claims 
Public 
Appendix A 1 Coefficient estimates from an ARIMA (1,1,2)(1,0,0)12 with a ramp 
intervention function for the volume of generic medication for publicly insured 
patients.  
Model Parameter  Estimate Standard Error T P-value 
Moving Average, Lag 1 -0.53140 0.1889 -2.8127 0.0056 
Moving Average, Lag 2 0.26519 0.0905 2.9294 0.0040 
Autoregressive, Lag 1 -0.61114 0.1855 -3.2948 0.0013 
Seasonal Autoregressive, Lag 12 0.36837 0.0876 4.2062 <0.0001 
Ramp: October 2006 36.45401 244.4055 0.1492 0.8817 
Ramp: July 2010 71.52658 341.6514 0.2094 0.8345 
Private 
Appendix A 2 Coefficient estimates from an ARIMA (1,1,0)(1,1,0)12 with a ramp 
intervention function for the volume of generic medication for privately insured 
patients.  
Model Parameter  Estimate Standard Error T P-value 
Autoregressive, Lag 1 -0.13752 0.0888 -1.5490 0.1239 
Seasonal Autoregressive, Lag 12 -0.52740 0.0814 -6.4786 <0.0001 
Ramp: October 2006 35.40628 42.3358 0.8363 0.4045 
Ramp: July 2010 11.47448 42.2359 0.2717 0.7863 
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Generic Percentage Dispensed 
Public 
Appendix A 3 Coefficient estimates from an ARIMA (1,0,3) with a ramp 
intervention function for the generic percentage dispensed for publicly insured 
patients. 
Model Parameter  Estimate Standard Error T P-value 
Intercept 0.23945 0.0072 33.0394 <0.0001 
Moving Average, Lag 1 -0.61511 0.1188 -5.1782 <0.0001 
Moving Average, Lag 2 -0.13376 0.1457 -0.9181 0.3602 
Moving Average, Lag 3 -0.41399 0.0901 -4.5949 <0.0001 
Autoregressive, Lag 1 0.59099 0.1133 5.2148 <0.0001 
Ramp: October 2006 -0.0007306 0.000371 -1.9693 0.0509 
Ramp: July 2010 0.00159 0.0012 1.3771 0.1707 
Private 
Appendix A 4 Coefficient estimates from an ARIMA (2,1,2) with a ramp 
intervention function for the generic percentage dispensed for privately insured 
patients. 
Model Parameter  Estimate Standard Error T P-value 
Moving Average, Lag 1 -1.50635 0.3160 -4.7670 <0.0001 
Moving Average, Lag 2 -0.52467 0.3093 -1.6965 0.0921 
Autoregressive, Lag 1 -1.43003 0.2825 -5.0613 <0.0001 
Autoregressive, Lag 2 -0.58807 0.2181 -2.6963 0.0079 
Ramp: October 2006 0.00084047 0.0018 0.4754 0.6353 
Ramp: July 2010 -0.0005194 0.0028 -0.1853 0.8532 
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Generic Dispensing Rate 
Public 
Appendix A 5 Coefficient estimates from an ARIMA (1,1,2)(0,1,1)12 with a ramp 
intervention function for the generic dispensing rate for publicly insured patients. 
Model Parameter  Estimate Standard Error T P-value 
Moving Average, Lag 1 -0.72789 0.1424 -5.1114 <0.0001 
Moving Average, Lag 2 0.19369 0.1009 1.9198 0.0571 
Seasonal Autoregressive, Lag 12 0.86526 0.1416 6.1110 <0.0001 
Autoregressive, Lag 1 -0.68437 0.1220 -5.6091 <0.0001 
Ramp: October 2006 -0.15685 1.8090 -0.0867 0.9310 
Ramp: July 2010 1.12843 2.1573 0.5231 0.6018 
Private 
Appendix A 6 Coefficient estimates from an ARIMA (1,1,0)(1,1,0)12 with a ramp 
intervention function for the generic dispensing rate for privately insured patients. 
Model Parameter  Estimate Standard Error T P-value 
Autoregressive, Lag 1 -0.13456 0.0890 -1.5124 0.1329 
Seasonal Autoregressive, Lag 12 -0.52859 0.0800 -6.6086 <0.0001 
Ramp: October 2006 0.27821 0.3371 0.8254 0.4107 
Ramp: July 2010 0.08750 0.3362 0.2603 0.7951 
 
110 
 
 
 
 
Total Cost of Antiglaucoma Medication 
Public 
Appendix A 7 Coefficient estimates from an ARIMA (13,1,2) with a ramp 
intervention function for the total cost of claims for publicly insured patients. 
Model Parameter  Estimate Standard Error T P-value 
Moving Average, Lag 1 0.72716 0.2365 3.0753 0.0026 
Moving Average, Lag 2 -0.53079 0.1517 -3.4997 0.0006 
Autoregressive, Lag 1 0.13542 0.2489 0.5441 0.5873 
Autoregressive, Lag 2 -0.14724 0.1052 -1.3995 0.1641 
Autoregressive, Lag 3 -0.01232 0.0902 -0.1367 0.8915 
Autoregressive, Lag 4 -0.35385 0.0807 -4.3861 <0.0001 
Autoregressive, Lag 5 0.20842 0.0939 2.2194 0.0282 
Autoregressive, Lag 6 -0.14893 0.0913 -1.6305 0.1055 
Autoregressive, Lag 7 -0.03254 0.0808 -0.4027 0.6878 
Autoregressive, Lag 8 -0.25196 0.0801 -3.1475 0.0021 
Autoregressive, Lag 9 0.07799 0.0910 0.8568 0.3932 
Autoregressive, Lag 10 -0.23442 0.0864 -2.7140 0.0076 
Autoregressive, Lag 11 0.05485 0.0859 0.6384 0.5244 
Autoregressive, Lag 12 0.53650 0.0906 5.9184 <0.0001 
Autoregressive, Lag 13 -0.02399 0.1935 -0.1239 0.9016 
Ramp: October 2006 13896 8400 1.6542 0.1006 
Ramp: July 2010 26426 13213 2.0000 0.0476 
Private 
Appendix A 8 Coefficient estimates from an ARIMA (2,1,2)(1,1,0)12 with a ramp 
intervention function for the total cost of claims for privately insured patients. 
Model Parameter  Estimate Standard Error T P-value 
Moving Average, Lag 1 -0.63805 0.1104 -5.7782 <0.0001 
Moving Average, Lag 2 -0.55208 0.1037 -5.3260 <0.0001 
Autoregressive, Lag 1 -1.12467 0.0731 -
15.3756 
<0.0001 
Autoregressive, Lag 2 -0.87176 0.0606 -
14.3757 
<0.0001 
Seasonal Autoregressive, Lag 12 -0.42154 0.0953 -4.4253 <0.0001 
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Ramp: October 2006 1487 2313 0.6427 0.5216 
Ramp: July 2010 2764 2329 1.1868 0.2376 
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